The Efficacy and Mechanism of Action of HDAC Inhibitors in Triple Negative Breast Cancer by Azam, Mayur
 
University of Otago 
Department of Pharmacology 
Master of Science 
 
The Efficacy and Mechanism of Action of HDAC 


















Histone deacetylase inhibitors (HDACis) are a class of chemically heterogeneous anticancer 
agents which consist of a hydrophobic capping group, linker region, and Zn2+ chelating 
pharmacophore. Manipulation of these three regions, such as the incorporation of a pyridine 
capping group, and hydroxythiopyridone Zn2+ binding group has yielded Jazz-90, and M1S 
and M2S, respectively. Alongside vorinostat, these HDACis were tested for their cytotoxicity 
and activity in triple negative MDA-MB-231 and MDA-MB-468 breast cancer cells. The novel 
compound Jazz-90 displayed the greatest cytotoxic potency in MDA-MB-231 cells  
(EC50 1.14 μM) while M1S had an EC50 of 1.66 μM in MDA-MB-468 cells. Time-course 
cytotoxicity studies showed the compounds to have a cytostatic effect at the EC50 concentration 
(1X) and a cytotoxic effect at four-fold the EC50 concentration (4X). Furthermore, the effect 
on protein expression was determined using Western blotting at 24 h post-treatment. Relative 
to their cytotoxicity, the EC50 of vorinostat (2.10 μM) showed the greatest increase in 
acetylated histone-H3 protein expression followed by 1X Jazz-90, 1472% and 1041%, 
respectively, compared to control in MDA-MB-231 cells; a similar trend was seen in MDA-
MB-468 cells. Compared to vehicle control, only 4X of M1S (6.66 μM) and M2S (17.17 μM) 
significantly increased acetylated histone-H3 expression in MDA-MB-468 cells, 11404% and 
10795%, respectively. Cell cycle protein analysis revealed that compared to control 1X of 
vorinostat, M1S, and M2S significantly downregulated cyclin B1 expression in MDA-MB-231 
cells by 56%, 65%, and 29%, respectively, suggesting the compounds to induce G2/M-phase 
arrest. Interestingly, 1X of M1S and M2S were found to significantly increase cyclin D1 
expression in MDA-MB-231 cells by 122% and 97%, respectively, suggesting that the 
compounds promote progression through the G1-phase. No change in total cyclin E2, Hsp90, 
or NF-κB p65 protein expression was seen in either cell line, p53 in MDA-MB-231 cells, or 
nuclear Hsp90 and nuclear NF-κB p65 in MDA-MB-468 cells. Thus, our findings provide 
evidence of the cytotoxic potency of Jazz-90, M1S, and M2S, but limited HDAC inhibitory 
effects in TNBC cells in vitro, hence warranting further modulation of the capping and Zn2+ 
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Histone deacetylases (HDACs) play a crucial role in silencing tumour suppressor genes 
and regulating non-histone proteins by modifying their post-translational status. HDAC 
inhibitors (HDACis) are able to reactivate tumour suppressor genes and inhibit tumour cell 
growth by suppressing malignant signalling, inducing cell cycle arrest, and promoting 
apoptosis, and are thus being evaluated in clinical trials as a breast cancer therapy 
(NCT00368875; NCT00719875). Breast cancer constitutes the highest rate of cancer 
registrations in New Zealand women, with 3308 cases occurring in 2016 alone (Ministry of 
Health, 2018). Triple negative breast cancer (TNBC) is defined histologically by a low level 
(≤10% cells positive) of oestrogen receptor (ER) and progesterone receptor (PR) expression, 
in addition to the lack of human epidermal growth factor-2 (HER2) overexpression or gene 
amplification (Badve et al., 2011). Analysis of proteins regulated by HDACis would improve 
our ability to define and characterise their molecular targets and determine their potential as an 
TNBC therapy. In light of recent research by the Hanif laboratory which demonstrated potent 
cytotoxicity of novel hydroxamate and hydroxythiopyridone HDACis at nanomolar 
concentrations in various cancer cell lines in vitro, the current study proposed to explore the 
mechanism and efficacy of three novel HDACis Jazz-90, M1S, and M2S, alongside a 
comparative established HDACi, vorinostat, in an in vitro model of TNBC.   
 
1.1  Epigenetic Control of Gene Expression 
In eukaryotic cells DNA is packaged into chromatin fibres to achieve compaction, enabling 
the entire genome to fit within the nucleus. This enables DNA transcription, replication, and 
repair, to occur when necessary. Using light microscopy, it was observed that chromatin exists 
in two elementary forms, dense and transcriptionally inactive heterochromatin with poor 
histone acetylation, and disperse and transcriptionally active euchromatin with high histone 
acetylation (Grunstein, 1997). It is now known that conversion between these two forms is 
regulated by nucleosomal modifications. 
 
Nucleosomes consist of DNA segments that are 147 bp long wrapped around a cylindrical 
histone octamer, which consists of two of each four core histone proteins H2A, H2B, H3, and 
H4 (Thatcher et al., 1994). The basic structure of chromatin is an array of nucleosomes 11 nm 
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in diameter resembling beads on a string. Interactions between neighbouring nucleosomes form 
denser structures which themselves undergo further folding, coiling, and packaging ultimately 
forming chromosomes. All four core histones consist of 20-24% positively charged lysine and 
arginine residues and have a molecular weight of 11-17 kDa, making histones densely 
positively charged (Panyim et al., 1971). This dense positive charge encourages intercalation 
of histones with the negatively charged phosphate backbone of DNA leading to compact 
chromatin folding. However, despite these strong atomic linkages nucleosomes are highly 
dynamic as the histone octamer is able to slide along DNA assisted by ATP-dependent 
chromatin remodelling enzymes, and ejected by post-translational modification of their 
protruding N-terminal tails as a result of ubiquitylation, methylation, phosphorylation, 
sumoylation, and acetylation (Wang et al., 2008). 
 
1.1.1 Role of Core Histone Acetylation 
A major factor regulating the degree of chromatin condensation is histone acetylation. 
Neutralisation of the positive charge on lysine residues on histone tails disrupts the electrostatic 
attraction between histone and phosphate groups on DNA, resulting in chromatin 
decondensation which promotes transcriptional activation (Vaquero et al., 2003). 
Hyperacetylation has shown to have little effect on the physiological stability of nucleosomes 
but has shown to inhibit chromatin folding into 30 nm chromatosome fibres (Simpson, 1978; 
Vidali et al., 1978;). As evidence of this Tse et al., (1998) assembled hyperacetylated HeLa 
histone octamer consisting of 12 tandem repeats of 208 bp DNA and looked for changes in 
chromatin folding patterns. Hyperacetylation completely inhibited higher order folding with a 
sedimentation velocity of 1.20-1.45 AU compared to 1.30-1.90 AU in unacetylated 
nucleosomes, indicating a decrease in intermolecular bonding and formation of secondary 
structures. 
The balance between the acetylated and deacetylated states of chromatin is regulated by the 
interplay between histone acetyltransferases and HDAC enzymes, respectively (Peserico et al., 
2010). Histone acetyltransferases transfer acetyl groups to the N-terminal of histone lysine 
residues, which results in local expansion of chromatin and enhanced accessibility of 
transcription factors to bind DNA, whereas HDACs act to catalyse the removal of acetyl 




1.1.2 Histone Deacetylase Mechanism of Action 
 HDACs are classified into four phylogenetic groups based on their sequence homology to 
yeast enzymes in which HDACs were first found (Dokmanovic et al., 2007; Table 1.1). Class 
III HDACs consist of sirtuins, which contains Zn2+ binding sites not accessible by hydroxamate 
HDAC inhibitors like trichostatin A and vorinostat. HDACs function in concert within multi-
protein complexes such as the ER, p53, retinoblastoma protein (Rb), and metastasis-associated 
protein, that are recruited to specific sites of the genome which in turn generate the spectrum 
of expressed and silenced genes producing the characteristic expression profiles responsible 
for the malignant phenotype of cancer cells (Ng and Bird, 2000). 
 
The mechanism of histone deacetylation occurs via a charge relay system consisting of two 
adjacent histidine residues, two aspartate residues, and the presence of a Zn2+ ion at the catalytic 
site (Bonomi et al., 2015; Fig 1.1). The carbonyl oxygen of the N-acetyl amide of the acetylated 
lysine residues, two carboxylate ions from two aspartate residues, and imidazole side chain 
from a histidine residue forms stabilising coordinate bonds with a Zn2+ cation at the HDAC 
catalytic centre. Zn2+, Asp-934, Asp-840, His-842, His-803, and His-802 coordinate and 
polarize an adjacent water molecule for nucleophilic attack of the acetyl carbonyl carbon, 
forming a tetrahedral intermediate stabilised by Zn2+ and His-803 (residue numbers based on 
HDAC4). The tetrahedral intermediate collapses forming acetate and lysine, with Histone-803 
acting as a Brønsted acid by protonating the ɛ-amine product.  
Table 1.1 Classification of the HDAC Family 
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1.2 Implications of Histone Deacetylase Activity in Triple Negative Breast 
Cancer 
Although the implications of the epigenetic code are not fully understood in the context of 
breast cancer, a low level of histone-H3 and histone-H4 acetylation has been reported to be 
associated with a TNBC phenotype and poor patient outcomes. Elsheikh et al., (2009) reported 
that high levels of the H3K18ac marker, as determined by the Histo-score protocol, in breast 
cancer correlated with a triple negative phenotype, where patient samples presented 
significantly lower levels of the ER, PR, and HER2, along with loss of the basal marker CK14 
and tumour suppressor BRAC1 protein expression implicating malignant HDAC activity to be 
associated with a TNBC presentation. Breast cancers with a H3K9ac marker had a similar 
clinical profile, where samples expressed significantly lower levels of ER, PR, BRCA1, but 
not HER2 (p = 0.07). Furthermore, the study also found low levels of H3K9ac and H4K16ac 
were significantly associated with a larger tumour size (>1.5 cm), while H4K16ac was 
independently associated with vascular invasion, indicating histone modifications to correlate 
with poor prognostic TNBC characteristics. Assessment of the relationship between the global 
histone acetylation and clinical patient outcomes among the entire breast cancer patient cohort 
(n = 880) showed that as compared to high levels of acetylation, a low level of acetylation was 
associated with a shorter disease free survival period (hazard ratio (HR) 0.90, P = 0.051) and 
worse breast cancer specific survival (HR 0.8, P = 0.004). A high level of H3K18ac was also 
found to be protective against breast cancer specific mortality (HR 0.47, P = 0.046) and non-
Figure 1.1 The mechanism of HDAC4 deacetylase activity (Bonomi et al., 2015) 
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site specific relapse (HR 0.448, P = 0.011). Together provides evidence that modification, 
namely histone-H3 and histone-H4 acetylation, plays a significant protective role regarding the 
clinical outcomes of patients with breast cancer, including those with TNBC. In essence, this 
data highlights the need to explore the efficacy of HDAC modulators in TNBC.  
 
1.3 Mechanisms of Histone Deacetylase Activity 
1.3.1 Cytotoxicity  
Both the intrinsic and extrinsic apoptotic pathways have shown to be regulated by HDAC 
activity in TNBC. The intrinsic apoptotic cascade initiates apoptosis through non-receptor 
mediated stimuli such as DNA damage induced by HDAC inhibition which promotes opening 
of mitochondrial permeability transition pores leading to loss of the mitochondrial 
transmembrane potential and release of pro-apoptotic proteins (Crompton, 1999). The extrinsic 
pathways involve engagement of tumour necrosis factor receptors by their cognate ligands 
followed by formation of a death effector domain and caspase-8 activation (Kantari and 
Walczak, 2011).  
  
1.3.1.1 Intrinsic Apoptotic Cascade 
The anti-apoptotic BCL2 family of proteins are located on the outer mitochondrial membrane 
and prevent leakage and subsequent activation of pro-apoptotic cytochrome C enzyme (Sharpe 
et al., 2004). Activation of the intrinsic cascade occurs when stress sensors BAD and BIM 
activate pro-apoptotic effects BAK and BAX, which oligomerise into a pore structure and 
insert into the outer mitochondrial membrane permitting the release of cytochrome C into the 
cytosol. Cytochrome C binds Apaf1 facilitating formation of the apoptosome, a large 
quaternary protein structure which recruits and activates pro-caspase-9. Activated caspase-9 
then activates executioner caspases-3, -6, and -7, initiating the execution phase of apoptosis. In 
the execution phase, caspases activate cytoplasmic endonucleases which degrade nuclear 
material, and proteases which degrade nuclear and cytoskeletal proteins. The executioner 
caspases cleave various substrates such as cytokeratins, poly ADP ribose polymerase (PARP), 
fodrin, actin, and gelsolin leading to morphological and biochemical changes seen in apoptotic 
cells such as blebbing (Elmore, 2007). 
  
The involvement of HDACs in the intrinsic cascade was reported on by Pidugu et al., (2017), 
who demonstrated that selective inhibition of HDAC8 promoted activation of the intrinsic 
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apoptotic cascade. Western blotting and real time quantitative polymerase chain reaction (RT-
qPCR) analysis of a TNBC MDA-MB-231 cell line treated with 0.1 μM of (R)-2-amino-N-((5-
phenyl-1,3,4-oxadi-azol-2-yl)methyl)propanamide (10b), a novel HDAC inhibitor, showed 
downregulation of only HDAC8, while having no effect on other class I HDACs, compared to 
vehicle treated controls. Subsequent protein analysis revealed that HDAC8 inhibition by 0.1 
μM of 10b correlated with a 2.33-fold decrease of Bcl-2, 25-fold increase of cytochrome C, 7-
fold increase in cleaved PARP, a 1.8-fold increase in acetylated p53, and a 2-fold increase in 
caspases-3 activity, with no significant change in caspases-8 activity, as compared to vehicle 
treated MDA-MB-231 cells (Pidugu et al., 2017). Based on this data the study concluded 
inhibition of HDAC8 prevents deacetylation and hence promotes p53 activity, which results in 
a decrease in the anti-apoptotic activity of Bcl-2 promoting mitochondrial membrane 
permeability and cytochrome C release, leading to activation of executioner caspases and 
apoptosis in TNBC cells in vitro. Demonstrating HDAC8 inhibition to induce cell death 
through the intrinsic apoptotic cascade via promotion of p53 activity in TNBC in vitro. 
HDACs also play a role in suppressing pro-apoptotic signalling molecules such as BIM in 
TNBC. Huang and Ling (2017) reported that MDA-MB-231 cells treated with 2.5 nM of a 
class I, II and IV HDACi (also known as a pan-HDACi), panobinostat, induced a 3-fold 
increase in the proportion of apoptotic cells compared to vehicle treated controls after 24 h, 
which correlated with an increase in cleaved PARP and BIM protein expression at this time 
point. Further experimentation using RT-qPCR showed 2.5 nM of panobinostat upregulated 
mRNA expression of BIM in TNBC cell lines MDA-MB-231 and MDA-MB-468   4- and 5-
fold, respectively, 24 h post-treatment, suggesting altered expression of BCL2L11. The 
mechanism of apoptosis was then elucidated to occur through enhanced acetylation of the 
enhancer region (50-1500 bp sequence bound by protein activators to increase the likelihood 
of transcription) of BCL2L11. Using chromatin immunoprecipitation (ChIP) qPCR, the authors 
determined that panobinostat significantly increased H3K27ac expression at the enhancer-1 
region of BCL2L11 in MDA-MB-231 and MDA-MB-468 cells 5.0- and 5.4-fold, respectively, 
and at the enhancer-2 region 6.0- and 4.0-fold, respectively, as compared to vehicle treated 
controls (Huang and Ling, 2017). This data shows that in TNBC class I, II, and IV HDACs act 
to suppress the expression of pro-apoptotic sensors, such as BCL2L11, by removing pro-
transcriptive acetylation markers at gene enhancer regions promoting the formation of 
heterochromatin and ultimately inhibiting apoptosis, which was subsequently found to be 
reversible through the use of HDACis. The efficacy of HDAC inhibition to overcome 
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mechanisms promoting TNBC cell viability and induce controlled cell death incites that further 
investigations into their mechanisms underlying cytotoxicity should be explored. 
 
1.3.1.2  Extrinsic Apoptotic Cascade 
The extrinsic pathway is initiated when ligand homotrimers tumour necrosis factor (TNF), 
FAS ligand (FASL), or TNF-related apoptosis-inducing ligand (TRAIL) bind their cognate 
receptor promoting formation of death domains and the death inducing signalling complex 
(DISC). A high local concentration of pro-caspase-8 at the DISC undergoes activation to 
caspases-8 and promotes autoproteolytic activation of executioner caspases-3, -6, and -7, 
leading to the execution phase of apoptosis (Kantari and Walczak, 2011). 
 
The involvement of HDACs in the extrinsic cascade was reported on by Pledgie-Tracy et al., 
(2007), who showed that HDAC inhibition promotes the activation of the extrinsic apoptotic 
mediators in TNBC in vitro. For example, 25 μM of sulforaphane (a thio based pan-HDACi) 
increased the cleavage of pro-capsase-8 and induced the expression of FASL while having no 
effect on cytochrome C expression in MDA-MB-231 cells compared to vehicle treated 
controls, demonstrating HDAC inhibition to promote activation of the extrinsic apoptotic 
cascade. Pledgie-Tracy et al., (2007) were not able to determine the pharmacodynamic activity 
of sulforaphane, however a complementary study by Arcidiacono et al., (2018) investigating 
sulforaphane in human melanoma suggests that the compound promotes the transcriptional 
activity of p53 consequently increasing FASL and FAS receptor expression, similar to the 
activity of HDACi 10b. However, in contrast to these findings microarray data generated by 
Tate et al., (2012) showed that 100 nM of panobinostat induced a 9.14-fold increase in FASLG 
gene expression alongside a 5.79-fold decrease in TP53 gene expression in MDA-MB-231 
cells as compared to vehicle control, indicating HDACi mediated promotion of FASL 
engagement through enhanced receptor expression does not exclusively necessitate increased 
stabilising acetylation, as seen with 10b, or upregulation, as seen with sulforaphane, of p53. In 
addition, these findings demonstrate that different HDACis produce contrasting cytotoxic 
effects despite acting as broad pan-HDAC inhibitors, which occurs as result of their non-
histone protein inhibitory effects.  
The role of HDACis in the extrinsic apoptotic cascade in TNBC was also investigated by 
Librizzi et al., (2016) where MDA-MB-231 cells were treated with novel pan-HDACis 
followed by flow cytometric analysis of pro-caspase-8 cleavage. 10 μM of novel HDACi  
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N-hydroxy-N-[(3Z)-2-oxo-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-indol5-
yl]octanediamide and 29 μM of vorinostat increased the cleavage of pro-caspase-8 15.5- and 
18.4-fold, respectively, in MDA-MB-231 cells 72 h post-treatment as compared to vehicle 
control, further demonstrating the role of HDACs in the extrinsic apoptotic cascade to mediate 
cytotoxicity.  
 
1.3.2 Cell Cycle 
The ability of HDACis to inhibit proliferation occurs as a result of their capacity to inhibit 
cell cycle progression at different phases of the cell cycle, notably at G1, G2, and mitosis.  
 
1.3.2.1 G1 Arrest 
Progression through the cell cycle is controlled by the activation of cyclin-dependent kinases 
(CDKs) which associate with cyclins at specific stages of the cell cycle, forming cyclin/CDK 
complexes. Progression from G1 into S-phase requires the sequential activation of a GTPase 
called RAS in early-G1, cyclin D/CDK4/6 in mid G1, and cyclin E/CDK4 in late G1, though in 
breast cancer cells cyclin E/CDK2 can act redundantly in place of cyclin D/CDK4/6 to promote 
G1-phase progression (Foster et al., 2010; Gray-Bablin et al., 1996).  
 
RAS is activated by guanine nucleotide exchange factors and induces transcription of cyclin 
D1 through the MEK-ERK and PI3K/Akt/mTOR pathways which promote cyclin D1 mRNA 
translation (Mendoza et al., 2011). The cyclin D/CDK4/6 complex promotes the activation of 
cyclin E/CDK2 by sequestering CDK inhibitors from the CIP/KIP family of proteins (p21, p27, 
p57). The trimeric complex cyclin D/CDK4/6/CDK inhibitor translocates to the nucleus and 
phosphorylates multiple sites on p130/pRb, which relieves pRb repression of E2F (Susaki et 
al., 2007; Narasimha et al., 2014). E2F is a transcription factor which binds to the promoter 
site of CCNE1 and induces cyclin E transcription. Increase in cyclin E expression and 
sequestration of CDK inhibitors promotes accumulation of CDK inhibitor free cyclin E/CDK2 
complexes, which are then activated by phosphorylation of the T-loop of CDK2 by CDK 
activating kinases (Abbas et al., 2007). In late G1, CDK2 acts synergistically with CDK4/6 in 
inhibiting repressor E2F complexes, ultimately enhancing E2F mediated gene transcription of 
proteins required for S-phase progression (Ren et al., 2002). 
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HDACs have been shown to play a critical role in the progression of cells through G1 into          
S-phase. Senese et al., (2007) reported that siRNA knockdown of HDAC1 and HDAC3 
independently, and co-knockdown of both enzymes decreased the proliferation rate of an 
osteosarcoma cell line U2OS 45-fold and ER+/PR+/HER2- breast cancer cell line MCF-7  
2.7-fold, as compared to scrambled siRNA treatment, suggesting HDAC inhibition may 
prevent cell cycle progression and consequently proliferation. The authors showed siRNA 
knockdown of HDAC1 independently and HDAC1 and HDAC2 concurrently increased 
protein expression of CDK2/4/6 inhibitor p21, suggesting HDAC1 and HDAC2 inhibition to 
be associated with G1 arrest (Senese et al., 2007). Cell cycle progression was investigated using 
fluorescence activated cell sorting, where U2OS cells were synchronised to G1/S-phase using 
a double thymidine block for 24 h followed by block release using a nocodazole containing 
medium. Subsequent cell sorting showed that 24 h after block release 45% of U2OS cells 
treated with HDAC1 siRNA remained in G1/S-phase compared to 18% treated with scramble 
siRNA, confirming HDAC1 to play a key role in G1 progression specifically through p21 
downregulation (Senese et al., 2007). To further highlight the role of HDAC1, cell sorting also 
revealed a 45-fold increase in the proportion of sub-G1 U2OS cells 24 h post-HDAC1 siRNA 
transfection indicating the need for HDAC1 activity in tumourigenic cells to promote G1 
progression and proliferation. A similar finding was reported by Glaser et al., (2003) who 
treated the HeLa cervical cancer cell line with 100 nM of HDAC3 siRNA. Cell sorting showed 
a 10% increase in the proportion of sub-G1/G1 HeLa cells 72 h post-transfection compared to 
control. 
Investigations in colorectal and cervical cells by Huang et al., (2005) also demonstrated the 
significance of HDACs in G1 regulation. In comparison to normal matched mucosa, RT-qPCR 
analysis of patient colorectal cancer samples showed a 2.0- and 2.3-fold increase in HDAC1 
and HDAC2 mRNA, respectively, which correlated with a 60% and 45% increase in HDAC1 
and HDAC2 protein expression, determined by immunohistochemistry. The increase in 
HDAC2 expression was inversely correlated with p21 mRNA which was shown to be 
reversible through siRNA silencing of HDAC2, demonstrating an inverse causative correlation 
between HDAC2 activity and p21 expression. HeLa cells transfected with HDAC2 siRNA 
experienced a 1.8-fold increase in p21 mRNA and a 4.0-fold increase in p21 protein expression 
compared to scramble siRNA treated HeLa cells 48 h post-transfection, indicating HDAC2 to 
inhibit p21 gene and protein expression. However, HDAC2 silencing did not correlate with G1 
arrest, though a 9% increase was observed in the proportion of sub-G1 cells in comparison to 
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the scrambled siRNA treatment, which may have been due to rapid transition from cell cycle 
arrest to apoptosis before 48 h when cell cycle analysis was performed.  
 
Though Salto-Tellez and Hooi (2005) did not observe G1 arrest through HDAC2 siRNA in 
HeLa cells, Harms and Chen (2007) reported HDAC2 knockdown to induce G1 arrest in      
MCF-7 cells indicating that there may be differences in HDAC significance between different 
cancers and the contrasting importance of HDAC2 in breast cancer. The authors generated 
MCF-7 cells which inducibly expressed shRNA targeting HDAC1 or HDAC2 after exposure 
to tetracycline. 4.5 μM of tetracycline increased the proportion of HDAC2-inducible MCF-7 
cells in G1 from 44.2% at baseline to 58.2% in the treatment group 96 h post-tetracycline 
exposure. G1 arrest was then shown to occur due to release of HDAC2 inhibition on p53-
dependent transcription of p21, where tetracycline mediated induction of HDAC2 shRNA was 
found to induce p53 and p21 protein expression as would be expected based on findings in 
HeLa and U2OS cells. A subsequent p21 luciferase reporter assay showed that lack of p53 
expression resulted in a 2-fold decrease in p21 protein expression compared to p53+/+ MCF-7 
cells, implicating the involvement of p53 activity in p21 protein expression. Then to link 
HDAC2 activity to p53 mediated p21 expression, knockdown of HDAC2 in p53+/+ MCF-7 
cells was found to increase p21 luciferase reporter activity 1.7-fold compared to p53+/+ 
HDAC2+/+ MCF-7 cells, confirming that HDAC2 played an inhibitory role in p53-p21 activity. 
Based on these findings, HDAC2 knockdown releases p53 inhibition permitting p21 induction 
and consequently G1 cell cycle arrest in breast cancer cells. However, in contrast to MCF-7 
cells suppression of p53 activity by HDACs may be beneficial in the TNBC subtype suggested 
by in vitro investigations by Hui et al., (2006). It has been established TNBC cells frequently 
express mutant forms of p53, as seen in MDA-MB-231 and MDA-MB-468 cells, and at higher 
protein levels than wild type p53 found in MCF-7 cells (Olivier et al., 2002). The authors 
reported siRNA silencing of phospholipase D2, an inhibitor of wild type p53 activity, in      
MDA-MB-231 cells to be associated with an 80% decrease in p53 protein levels and a 40% 
decrease in cell viability as compared to control scrambled siRNA treatment after a period of  
72 h (Hui et al., 2006). This finding indicates that in contrast to wild type p53, the mutant form 
seen in MDA-MB-231 cells is positively regulated by phospholipase D2 and likely promotes            
MDA-MB-231 cell viability. Based on these contrasting observations it is critical to determine 
whether modulators of HDAC activity positively or negatively regulate p53 signalling and link 
these findings to associated changes in TNBC cell viability.  
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1.3.2.2 G2/M Arrest 
The involvement of HDACs is not limited to the G1-phase of the cell cycle and their role in 
the G2/M transition has also been an area of interest. G2 is the second sub-phase of interphase 
and follows successful completion of S-phase where the cell’s DNA is replicated. 
 
  Entry into mitosis is regulated by the level of active cyclin B1/CDK1, where transcription of 
cyclin B1 begins at the end of S-phase and is mediated by p53, p21, c-Myc, NF-Y, and TFE3 
(Lindqvist et al., 2009). After translation, cyclin B1 accumulates in the cytoplasm where it 
binds to and activates CDK1 by sterically moving away an inhibitory T-loop from the active 
site of the serine/threonine kinase. CDK1 activity is then modulated by Wee1 and Myt1 which 
perform inhibitory phosphorylation of Tyr-15 and Thr-14, respectively (Tran et al., 2010). 
CDK1 can then be reactivated by the dephosphorylating activity of Cdc25 at both the Tyr-15 
and Thr-14 residues. Activated CDK1 is then able to perform inhibitory phosphorylation of 
Wee1 kinase and stimulatory phosphorylation of Cdc25, forming a positive feedback loop of 
CDK1 activity. Cyclin A/CDK2 also regulates the activation of cyclin B1/CDK1 and entry into 
mitosis. Cyclin A/CDK2 activity begins in early S-phase and increases during G2, where Cdc25 
dephosphorylates and activates CDK2, which in turn inhibits Wee1 kinase activity (Mitra and 
Enders, 2007). Nuclear translocation of cyclin B1/CDK1 is promoted by phosphorylation of 
cyclin B1’s cytoplasmic retention site. Once in the nucleus cyclin B1/CDK1 promotes gene 
expression of proteins required for mitosis such as nuclear lamina, centrosomal proteins, and 
microtubule associated proteins (Takizawa and Morgan, 2000). 
 
Inhibition of class I and II HDACs induces G2/M-phase arrest, implicating their significance 
in G2-phase cell cycle progression. For example, Zhang et al., (2014) investigated the efficacy 
of N1-(3-bromobenzyl)-N7-hydroxy-N1-(2,4-dimethoxyphenyl)-heptanediamid (YF479), a 
HDAC1, 3, and 6 inhibitor, to induce cell cycle arrest and apoptosis in TNBC cells in vitro.  
5 μM of YF479 downregulated the expression of cyclin B1 and CDK1 compared to vehicle 
treated MDA-MB-231 cells 48 h post-treatment. The decrease in cyclin B1 and CDK1 was 
shown to correlate with G2/M arrest, where 5 μM of YF479 increased the proportion of      
MDA-MB-231 cells in G2/M-phase from 12% in controls to 31% in the treatment group              
24 h post-treatment. Similar results were produced by Li et al., (2015) using a HDAC1, 4, and 
6 inhibitor 6-[2-[2-(3-bromophenyl)-4-oxo-3-thiazolidinyl]phenoxy]-N-hydroxy-hexanamide 
(LW479). 20 μM of LW479 increased the proportion of MDA-MB-231 cells in G2/M-phase 
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from 25.90% in control to 41.48% in the treatment group 24 h post-treatment. Together this 
data provides evidence of the critical role of HDACs in regulating cell cycle progression in 
TNBC. These findings demonstrate that to determine the antiproliferative mechanisms of 
HDACis it is crucial to investigate changes in cell cycle progression and associated protein 
expression. 
1.3.3 Heat Shock Protein 90 Facilitated NF-κB Signalling 
Aberrant canonical NF-κB signalling contributes to the development and progression of 
mammary adenocarcinomas by promoting inflammation, invasion, and metastasis (Biswas et 
al., 2004; Biswas et al., 2003). Heat shock protein 90 (Hsp90) is a chaperone protein whose 
function is negatively modulated by acetylation, which has been linked to suppression of  
NF-κB signalling.  
 
Among MCF-7, T47D, and MDA-MB-231 cells, Shibata et al., (2002) reported that  
MDA-MB-231 cells to express the highest level of vascular endothelial growth factor (VEGF) 
mRNA, a pro-angiogenic factor known to promote TNBC vascularization and metastasis. 
Inoculation of dominant negative NF-κB p65 adenovirus into MDA-MB-231 cells produced a 
dose response decrease in VEGF mRNA expression, where a multiplicity of infection of 100 
decreased VEGF mRNA 50% below control, suggesting inhibition of NF-κB p65 may inhibit 
TNBC malignancy. A complementary study was performed by Liu et al., (2010) looking at the 
effect of NF-κB p65 suppression on mammary tumour growth in vivo. Transgenic FVB mice 
harbouring HER2+ mammary epithelial cells with ponasterone A-inducible IκBα, a direct 
inhibitor of NF-κB p65, were 50% less likely to develop mammary tumours 8 weeks                  
post-ponasterone administration, and mice who did develop mammary tumours developed 55% 
fewer mammary tumours 5 weeks post-ponasterone administration as compared to IκBα 
deficient mice. To relate these findings to the TNBC subtype, Nakshatri et al., (1997) reported 
that in TNBC, a lack of ER protein expression promotes enhanced and constitutive NF-κB p65 
transcriptional activity. The authors reported that the progression of a rat mammary carcinoma 
cell line RM22-F5 from an ER+ non-malignant phenotype to a malignant ER- phenotype was 
accompanied by a 2-fold increase in NF-κB p65 transcriptional activity, determined using an 
electrophoretic mobility shift assay. To then investigate the effect of the ER on NF-κB p65 
activity, MDA-MB-231 cells were transfected with a chloramphenicol acetyltransferase 
reporter gene at RELA. Treatment of MDA-MB-231 cells with 0.5-10 μg of ESR1 expression 
vector, pSG5-HEGO, produced a dose-dependent decrease in RELA reporter activity from          
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2.5 AU at 0 μg to 0.4 AU at 10 μg of expression vector. These results demonstrate the 
development of malignant NF-κB p65 signalling in TNBC cells as well as the significance of 
this pathway relative to ER+ cell lines.  
Taken together these studies provide firm evidence of malignant NF-κB p65 signalling in 
breast cancer, where TNBC cells were demonstrated to have elevated levels of NF-κB p65 
signalling relative to ER+ cell lines, however inhibition of the pathway was shown to play a 
significant protective effect on tumour progression and metastasis. Interestingly, with respect 
to HDAC activity, hyperacetylation of Hsp90 has been shown to inhibit canonical NF-κB p65 
signalling.   
 
Hsp90 is a chaperone protein that is able to stabilise oncogenic proteins promoting breast 
cancer survival. Fiskus et al., (2007) reported that hydroxamate HDACis inhibit Hsp90 
function through hyperacetylation determined by a decrease in chaperone association with 
ERα. Specifically, 250 nM of dacinostat was found to increase Hsp90 acetylation, through 
inhibition of HDAC6 (Bali et al., 2005; Fuino et al., 2003), and decrease chaperone associated 
with ERα 8 h post-treatment as compared to vehicle control in MCF-7 cells. The study 
demonstrated that hyperacetylation of Hsp90 inhibited chaperone function, which has also been 
shown to be beneficial in in vitro models of TNBC. Furthermore, Caldas-Lopes et al., (2009) 
reported that the Hsp90 inhibitor 6-amino-8-[(6-iodo-1,3-benzodioxol-5-yl)thio]-N-(1-
methylethyl)-9H-purine-9-propanamine (PU-H71; IC50 51 ± 7 nM in MDA-MB-468) had 
potent cytotoxicity in TNBC cells in vitro with a median inhibitory concentration (EC50) of 
140 ± 5 nM in MDA-MB-231 cells and 65 ± 8 nM in MDA-MB-468 cells following a treatment 
period of 72 h. A follow up proteomic analysis of MDA-MB-468 cells treated with 1 μM of 
PU-H71 revealed several components of the NF-κB pathway to be downregulated following 
PU-H71 treatment, specifically interleukin-1 receptor kinase 1 (IRAK1), TAK1 binding 
protein 2 and 3 (Tab2/3), and NF-κB activated kinase (NAK). Physiologically the IRAK/Tab 
complex activates TAK1, which phosphorylates and activates inhibitor of NF-κB-β, which then 
phosphorylates IκBα releasing NF-κB p65 from its inhibited state. 1 μM of PU-H71 induced 
proteasome mediated depletion of IRAK1 and NAK, along with a 75% decrease in nuclear NF-
κB p65 expression, as compared to vehicle treated MDA-MB-231 cells 24 h post-treatment. 
This data indicates inhibition of Hsp90 activity inhibited NF-κB p65 nuclear translocation 
through inhibition of upstream regulators in TNBC in vitro. To date, no studies have linked 
HDACi-mediated inhibition of Hsp90 activity to changes in NF-κB p65 transcriptional activity 
in vitro. Given HDAC inhibitors are able to suppress Hsp90 chaperone activity through 
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enhanced acetylation, the current study will further explore whether HDAC inhibition 
modulates Hsp90 and NF-κB p65 expression and nuclear localisation in TNBC in vitro. 
 
1.4 Histone Deacetylase Inhibitors for Triple Negative Breast Cancer  
Current HDACis share a common pharmacophore consisting of a Zn2+ binding group which 
chelates to the catalytic Zn2+ ion at the HDAC active site, a capping group which binds to the 
surface of the active site pocket, and a linker between the Zn2+ chelator and cap (Fig 1.2). By 
inserting into the catalytic pocket HDACis block acetyl lysine substrate access to the active 
site consequently promoting accumulation of acetylated histone and non-histone proteins, 
hence act as competitive inhibitors of HDACs (Seto and Yoshida, 2014). HDACis are 
classified into various groups based on their chemical structure: hydroxamic acids (vorinostat, 
dacinostat, panobinostat), benzamides (SNDX-275, etinostat, MGCD0103), short-chain fatty 
acids (sodium butyrate, valproic acid, AN-9), cyclin peptides (romidepsin, apicidin), thiolates, 
carboxamides, and non-hydroxamic acids (Kim and Bae, 2011; Drummond et al., 2004; Miller 
et al., 2003). 
 
 
Figure 1.2 Pharmacophore model for Zn2+ dependent HDAC inhibitors 
HDAC inhibitors share a Zn2+ binding moiety at the HDAC catalytic pocket, a hydrophobic capping group, and a 
straight chain linker connecting the two pharmacophores exemplified by N-hydroxyformamide, benzene, and 
heptanamide, respectively, in vorinostat (Stankov et al., 2014). 
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The current study will investigate the efficacy of a novel hydroxamate N1-hydroxy-N8-(4-
(pyridine-2-carbothioamido)phenyl)octanediamide (Jazz-90), and two hydroxy-thiopyridone 
derivatives 1-benzyl-3-hydroxy-2-methylpyridine-4(1H)-thione (M1S) and 3-hydroxy-2-
methyl-1-phenethylpyridine-4(1H)-thione (M2S), alongside vorinostat in TNBC in vitro (Fig 
1.3). The efficacy of hydroxamate and hydroxythiopyridone derivatives have been investigated 
in TNBC and other neoplastic cell lines where they show efficacious anticancer potential 
(Table 1.2).  
 
 
Figure 1.3 Chemical Structure of vorinostat, Jazz-90, M1S, and M2S 
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Table 1.2 Chemical Structure and Potency of Hydroxamate and 




Table 1.2 Continued 
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1.4.1 Hydroxamate Derivatives 
Hydroxamate HDACis typically contain a zinc binding moiety represented by the 
hydroxamic acid group, which has high affinity for Zn2+ ions at the active site of class I, II, and 
IV HDACs. Initial clinical studies established vorinostat to be well tolerated in patients with 
cutaneous T-cell lymphoma, B-cell lymphoma, Hodgkin lymphoma, and other haematological 
and solid malignancies (Dickinson et al., 2009). Given the diverse anticancer properties of 
vorinostat, much effort has been made to explore other hydroxamate derivatives as a potential 
treatment option for breast cancer (Table 1.2).  
 
1.4.1.1 Vorinostat 
The discovery of hexamethylene bisacetamide, a non-HDAC that is inhibitor able to induce 
differentiation of neoplastic cells, and the attempt to overcome its severe adverse effects, 
particularly thrombocytopenia, lead to the development of vorinostat, a second generation 
hybrid polar agent with a 2500-fold greater potency and less toxicity than hexamethylene 
bisacetamide (Marks and Breslow, 2007). Vorinostat has shown efficacy as an HDACi against 
TNBC both in vitro and in vivo. 
 
In MDA-MB-231 cells, 5 μM of vorinostat caused a 126% increase in the proportion dead 
cells, which was associated a 165% increase in the proportion of G0/G1-phase cells, and a 
reduction in MDA-MB-231 cell migratory ability as compared to the vehicle treatment 24 h 
post-treatment (Feng et al., 2017). Then using RT-qPCR the authors showed that 5 μM of 
vorinostat stimulated a 3000% increase in cyclin E/CDK2 and cyclin D/CDK4/6 inhibitor p21 
mRNA expression as compared to vehicle treated MDA-MB-231 cells, concordant with G1-
phase arrest. The transcriptional regulation of p21 was then investigated using DNA-ChIP 
arrays, where 5 μM of vorinostat increased acetylation of H3K27ac, H3K18ac, and H4K5ac 
residues 2.5-10-fold at the promoter region of the p21 gene, CDKN1A, compared to vehicle 
treated MDA-MB-231 cells. This finding indicates that vorinostat promotes histone acetylation 
of the CDKN1A promoter by inhibiting HDAC activity leading to upregulation of CDKN1A 
transcription which ultimately promotes G0/G1-phase cell cycle arrest in TNBC in vitro.   
 
The efficacy of vorinostat has also been investigated in a metastatic brain TNBC cell line,  
231-BR (Palmieri et al., 2009). 0.5-10 μM of vorinostat was found to increase acetylation of 
histone-H3 (H3K9ac) and histone-H4 (H4K8ac) compared to vehicle treated 231-BR cells, 
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confirming vorinostat to be a HDACi. 5 μM of vorinostat was reported to induce a 300% 
increase in the number of 231-BR cells undergoing apoptosis which was associated with 
increased cleavage of pro-caspase-9, demonstrating apoptosis to occur through the intrinsic 
cascade. When investigating in vivo translation of histone acetylation, where BALB/c nude 
mice were inoculated with 175,000 231-BR cells followed by a 150 mg/kg intraperitoneal 
injection once daily for seven days showed no significant change in the proportion of acetylated 
histone-H3 or histone-H4 in metastatic brain slices when compared to vehicle treated mice. 
Similarly, cleavage of pro-caspase-3, a marker of the intrinsic apoptotic cascade, was not 
detectable in metastatic tissue slices. The study found contrasting in vitro and in vivo results 
despite vorinostat having a high blood brain barrier permeability surface area product of  
1.4 ± 0.3 × 10-4 mL/s/g. The lack of efficacy in vivo may have been a result of efflux transport 
out of neoplastic neurological tissue and homogenous distribution of vorinostat in the brain 
lowering drug efficacy below the localised concentration required, suggesting improvements 
in drug targeting and potency should be investigated. Further investigations in vitro showed 10 
μM of vorinostat increased the proportion of 231-BR cells in G0/G1-phase 27% above the 
vehicle treatment, indicating that the compound induced a G1 blockade, similar to findings by 
Feng et al., (2017). Cell cycle blockade was then demonstrated to occur due to DNA damage, 
where 5 μM of vorinostat increased the proportion of γ-H2AX foci, a histone marker of double 
stranded DNA breaks, 14-fold compared to vehicle treated 231-BR cells. DNA damage was 
found to be replicated in vivo, where brain slices from mice dosed with 150 mg/kg of vorinostat 
displayed 104% more γ-H2AX foci positive cells compared to vehicle treated mice. Together 
this data indicates that vorinostat induces DNA damage in a metastatic model of TNBC in vivo, 
however if this level of DNA damage was able to modulate metastatic tumour size was not 
established and further investigations are required. 
 
Given the limited efficacy of standard chemotherapy in TNBC patients Wawruszak et al., 
(2015) explored the efficacy of vorinostat in combination with cisplatin in an in vitro model of 
TNBC. The cytotoxicity of vorinostat alone in MDA-MB-231 cells was found be                      
EC50 2.18 ± 0.12 μM and cisplatin alone EC50 12.04 ± 2.47 μM, and a 1:1 ratio of 
vorinostat:cisplatin produced an EC50 value of 3.35 ± 0.97 μM (Table 1.2). In comparison to 
solo treatments, the combination of vorinostat and cisplatin was found to be antagonistic 
suggesting opposing mechanisms of action and poor combined efficacy. This limited synergy 
was also seen when looking at the effect of combination drug treatment on pro-caspase-3 
cleavage. 2.18 μM of vorinostat and 12.04 μM of cisplatin independently produced a 2- and 
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1.5-fold increase in caspases-3 activity, respectively, and the 1:1 combination treatment elicited 
a 2.75-fold increase as compared to control treated MDA-MB-231 cells 48 h post-treatment 
(Wawruszak et al., 2015). Similarly, using flow cytometry, 12.04 μM of cisplatin increased the 
proportion of MDA-MB-231 cells in S-phase 1.4-fold whereas 2.18 μM of vorinostat increased 
the proportion of cells in G1-phase 1.2-fold 48 h post-treatment, compared to control. In 
contrast, the combination treatment was found to stimulate a 1.2-fold increase in the proportion 
of MDA-MB-231 cells in S-phase and no change in the proportion of cells in G1-phase in 
comparison to control 48 h post-treatment. Limited cell cycle inhibition was likely observed as 
cisplatin acts as an alkylating agent which interferes with DNA replication in S-phase whereas 
vorinostat inhibits expression of cyclins and CDKs in G1-phase leading to alternate 
mechanisms of cell cycle arrest. Together this data indicates vorinostat and cisplatin do not 
work synergistically to induce cell death and cell cycle arrest in an in vitro model of TNBC.  
 
Mutation of p53 is found in the vast majority of TNBCs making the protein a target of 
particular interest (Turner et al., 2013). Based on this finding Wang et al., (2016) investigated 
vorinostat mediated inhibition of mutant p53 in TNBC in vitro. The cytotoxicity of vorinostat 
was reported to be 3.38 μM in MDA-MB-231 cells and 6.79 μM in another TNBC cell line  
BT-549. The authors then synchronised cell lines to G1 using thymidine double blocking 
followed by the addition of 2 μM of vorinostat. Concordant with previous studies, vorinostat 
significantly increased the proportion of MDA-MB-231 cells in G0/G1-phase 1.4-fold in 
comparison to the vehicle treatment 24 h post-treatment. In addition, 2 μM of vorinostat was 
found to downregulate Bcl-2 protein expression and upregulate Bax, Bim, cleaved caspase-3, 
and p21 expression in MDA-MB-231 cells compared to the vehicle treatment after 24 h, 
demonstrating vorinostat to induce apoptosis via the intrinsic apoptotic cascade (Wang et al., 
2016). Then, based on previous reports of vorinostat mediated stabilisation and activation of 
p53, the authors investigated changes in total p53 levels, phosphorylation status, and nuclear 
translocation. 12 h post-treatment 2 μM of vorinostat decreased total and phosphorylated levels 
of mutant p53 in comparison to the control treatment. To investigate changes in mutant TP53 
gene expression RT-qPCR was performed to measure levels of the mature and precursor p53 
transcript in MDA-MB-231 and BT-549 cell lines. In comparison to control, 2 h post-treatment 
of 2 μM of vorinostat caused a 9- and 4-fold decrease in precursor p53 mRNA in  
MDA-MB-231 and BT-549 cells, respectively, which was followed by a 1.7- and 1.25-fold 
decrease in mature p53 mRNA in MDA-MB-231 and BT-549 cells, respectively, 4 h post-
treatment. In contrast 2 μM of vorinostat was found to have no effect on wild type precursor 
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or mature p53 mRNA levels found in MCF-7 and A549 cells in comparison to the vehicle 
treatment, suggesting vorinostat to specifically downregulate mutant p53 found in  
MDA-MB-231 and BT-549 cells (Wang et al., 2016). To then determine the mechanism of 
mutant p53 transcriptional inhibition, the authors used siRNA to knockdown expression of 
HDAC8. HDAC8 knockdown resulted in a 2.5-fold decrease in precursor mutant p53 mRNA 
expression in MDA-MB-231 cells, whereas treatment with 5 μM of MS275, a class I HDAC 
inhibitor with no activity against HDAC8, produced no change in precursor mutant p53 mRNA 
when compared to vehicle treated control. This data demonstrates that in TNBC cells vorinostat 
mediated inhibition of mutant p53 expression occurs specifically through inhibition of nuclear 
HDAC8 activity. Previous studies have reported that YY1, a regulator of HDAC promoter 
specificity, binds at -102 to -96 of TP53, where acetylation of YY1 inhibits its DNA binding 
activity and ultimately targeted gene transcription (Yao et al., 2001). Using a luciferase TP53 
reporter assay the authors demonstrated 2 μM of vorinostat caused a 3.5-fold decrease in 
luciferase activity at TP53 under the control of promoter containing a consensus YY1 binding 
site but not a promoter with a deleted YY1 site, in comparison to vehicle control treated  
MDA-MB-231 cells. The interaction of HDAC8 and YY1 was then investigated, where  
MDA-MB-231 cells were transfected with YY1 with an overexpressed deacetylation site at the 
170-200 region. Transformed MDA-MB-231 cells were treated with 2 μM of vorinostat 
showed a significant increase in YY1 acetylation at the 170-200 region compared to wild type 
MDA-MB-231 cells 2 h post-treatment (Yao et al., 2011). To then determine the role of 
HDAC8 and YY1 in TNBC cell viability the authors utilised siRNA to knockdown the 
expression of HDAC8 and YY1 in MDA-MB-231 cells and then investigated changes in cell 
viability using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 
colony formation assay. Transfection with HDAC8 siRNA was found to cause an 80% decrease 
and YY1 siRNA a 30% decrease in MDA-MB-231 cell viability, which were both found to be 
associated with a decrease in colony formation, as compared to scrambled siRNA transfected 
MDA-MB-231 cells 72 h post-transfection (Yao et al., 2011). Together this data indicates 
vorinostat to inhibit HDAC8 resulting in hyperacetylation of the 170-200 region of YY1 




Dacinostat was discovered as a result of a drug screen by Novartis on the structural analogs 
of NVP-LAK974, a HDAC inhibitor with high potency in vitro but poor efficacy in vivo 
(Remiszewski, 2003). 
  
Given the pro-angiogenic nature of TNBC Qian et al., (2004) investigated the efficacy of 
dacinostat as an anti-angiogenic therapy in an in vitro model of TNBC. 250 nM of dacinostat 
caused an 80% decrease in cell viability 48 h post-treatment in comparison to vehicle treated 
MDA-MB-231 cells, indicating the HDACi to have cytotoxic potency at nanomolar 
concentrations. Further investigation into the mechanism of dacinostat cytotoxicity showed 
100 nM of the compound to upregulate histone-H3 acetylation and p21 mRNA and protein 
expression in MDA-MB-231 cells 24 h post-treatment in comparison to control, suggesting 
that dacinostat induced G1 arrest followed by cell death (Qian et al., 2004). Then looking at the 
anti-angiogenic potential, 1.25 μM of dacinostat decreased the proliferation and survival of  
50 ng/mL VEGF stimulated HUVECs by 85% below the vehicle treatment after 72 h. This was 
followed by in vitro and in vivo angiogenesis investigations using an endothelial cell tube 
formation assay and Matrigel plug assay in athymic nude mice. 200 nM of dacinostat was 
found to decrease HUVEC tube formation by 47.5% in comparison to the vehicle treatment 
after 15 h, similar to a 50% decrease in the number of microvessels in nude mice implanted 
with a Matrigel plug and treated with 40 mg/kg/day of dacinostat for 10 days compared to 
vehicle control treated mice (Qian et al., 2004). This data demonstrated HDACi dacinostat to 
have potent cytotoxicity and anti-angiogenic effects in vitro which was found to translate in 
vivo. To then investigate the anti-angiogenic mechanism of dacinostat the authors performed 
Western blotting and RT-qPCR analysis under normal and pro-VEGF hypoxic conditions 
looking for changes in VEGF and HIF-1α, a transcription factor which promotes VEGFA 
expression. 500 nM of dacinostat was found to completely inhibit HIF-1α protein and VEGF 
mRNA expression while having no effect on HIF-1α mRNA expression under both normal and 
hypoxic conditions in MDA-MB-231 cells in comparison to the vehicle control after 24 h (Qian 
et al., 2004). The authors then looked at the effect of dacinostat on TNBC tumour growth in an 
in vivo orthotropic MDA-MB-231 nude mouse model. Mice given 40 mg/kg/day of dacinostat 
intraperitoneally were found to have have significantly smaller tumour volumes compared to 
vehicle treated mice 30 days post-implantation, 500 mm3 vs 1250 mm3, respectively (Qian et 
al., 2004). In addition, in vitro anti-angiogenic findings were observed to correlate in vivo, 
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where TNBC tumours in mice given dacinostat displayed inhibition of HIF-1α, enhanced 
acetylation of histone-H3, and a 50% reduction in microvessel density in comparison to the 
vehicle treatment. Together this data indicates the HDACi dacinostat to inhibit TNBC cell 
viability through p21 upregulation and inhibit angiogenesis through suppression of HIF-1α 
mediated VEGFA transcription, where the latter was found to translate in vivo. 
Given that anticancer drugs commonly modulate DNA synthesis Hurtubise and Momparler 
(2006) investigated the anticancer mechanism of dacinostat in an in vitro model of TNBC. The 
cytotoxicity of dacinostat was reported to be EC50 52.7 nM in MDA-MB-231 cells after 48 h 
exposure (Table 1.2). The authors then looked at the ability of dacinostat to inhibit cell viability 
using a colony formation assay, where 26.4 nM was found to cause a 60% decrease in  
MDA-MB-231 colony formation compared to the vehicle treatment after 48 h. Next, they 
investigated the effect of dacinostat treatment on DNA replication by measuring the 
incorporation of radioactive thymidine into DNA. 39.5 nM of dacinostat caused a 50% 
decrease in DNA synthesis in comparison to the vehicle treatment in MDA-MB-231 cells 72 h 
post-treatment. This data provides evidence of the potent cytotoxicity of hydroxamate HDACis 
such as dacinostat and the compound’s ability to inhibit TNBC cell viability through 
suppression of DNA synthesis. 
 
1.4.1.3 Panobinostat 
The pan-HDACi panobinostat was discovered by Novartis based on their hit-to-lead drug 
discovery program (Atadja and Perez, 2017). Dacinostat derivatives with large alkyl groups at 
the 2-position of the indole ring showed the greatest antitumor efficacy in vivo but were not 
well tolerated with a 5-17% loss in total body weight at a dosage of 50 mg/kg. It was discovered 
that a compound with a methyl group at the 2-positon, panobinostat, showed the best overall 
in vivo profile.  
 
The efficacy of panobinostat against TNBC in vitro and in vivo was investigated by Tate et 
al., (2012), who demonstrated that 200 nM of panobinostat significantly increased histone-H3 
and histone-H4 acetylation 200-700% compared to the control treatment in four TNBC cell 
lines, MDA-MB-231, MDA-MB-157, MDA-MB-468, and BT-549, establishing the drug as an 
HDACi. The cytotoxicity of panobinostat, determined using a trypan blue assay, was reported 
to be EC50 100-200 nM, indicating the compound to have significant cytotoxicity at nanomolar 
concentrations and suggesting promising in vivo translation, which was then investigated 
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(Table 1.2). To determine the efficacy of panobinostat in vivo, MDA-MB-231 and BT-549 
xenografts were implanted into CB-17/SCID female mice followed by 10 mg/kg/day 
intraperitoneal injection of panobinostat 5 days/week for 4 weeks 14 days post-xenograft 
implantation. Mice inncolulated with 5 × 106 MDA-MB-231 cells and treated with 
panobinostat presented significantly lower tumour volumes compared to the vehicle treatment 
27 days post-treatment, 200 mm3 vs 800 mm3. Similarly, mice inoculated with 5 × 106 BT-549 
cells also presented significantly lower tumour volumes 27 days post-treatment, 200 mm3 vs 
600 m3, indicating effective translation of in vitro findings in vivo and efficacious reduction in 
TNBC proliferation and growth without a significant change in body weight. Interestingly, by 
using a Human Breast Cancer and Oestrogen Receptor Signalling RT2 PCR array, the authors 
reported that compared to control, 24 h post-treatment of 100 nM of panobinostat induced a 
31- and 24-fold increase in CDH1, an epithelial marker and tumour suppressor, in  
MDA-MB-231 and MDA-MB-468 cells, respectively, suggesting reversal of an epithelial 
mesenchymal transitory cellular morphology commonly seen in TNBC cells. Subsequent 
immunocytochemistry analysis showed 100 nM of panobinostat stimulated a 5-fold increase 
in the proportion of CDH1+ MDA-MB-231 cells alongside a 1.6-fold increase in E-cadherin 
protein levels compared to the vehicle treatment. Given that the highly aggressive nature of 
TNBC is characterised by invasion and metastatic dissemination, where loss of CDH1 
expression is crucial for epithelial to mesenchymal transition and is associated with poor 
clinical outcomes, panobinostat mediated induction of CDH1 may be indicative of decreased 
TNBC metastatic potential (Tate et al., 2012; Taube et al., 2010). This hypothesis was 
validated by Fortunati et al., (2014) who showed 50 nM of panobinostat to cause a 75-fold 
increase in E-cadherin expression in MDA-MB-231 cells compared to vehicle control 24 h 
post-treatment. Then using a scratch and transwell invasion chamber assay, the authors 
demonstrated 25 nM of panobinostat to decrease scratch closure rate by 50% and to decrease 
the proportion of invading MDA-MB-231 cells by 90% as compared to the vehicle control 24 
h post-treatment. Together this data establishes the cytotoxic potency and anti-invasive 
properties of the pan-HDACi panobinostat in vitro and in vivo. 
 
In addition, a novel mechanism was uncovered by Zhou et al., (2007) where panobinostat 
treatment was found to restore ER expression in MDA-MB-231 cells. 200 nM of panobinostat 
was found to increase ER protein expression in MDA-MB-231 cells which correlated with a 
concomitant increase in ER mRNA expression 24 h post-treatment compared to the vehicle 
control. To then assess the duration of ER upregulation, MDA-MB-231 cells were treated with 
 25 
100 nM of panobinostat for 24 h followed by washing, then maintenance in a drug free medium 
for 96 h. The authors found panobinostat treatment stimulated a 4-fold increase in ER mRNA 
expression 96 h after the drug was removed from media as compared to vehicle treated controls. 
ER re-expression was theorised to occur through disruption of the HDAC1/DNMT1/SUV39H1 
repressor complex bound to the ESR1 promoter. Using a ChIP assay the authors showed  
100 nM of panobinostat decreased recruitment of HDAC1 and DNMT1 to the ESR1 promoter 
in MDA-MB-231 cells 24 h post-treatment compared to vehicle control, indicating HDAC1 
inhibition can release transcriptional inhibition mediated by DNMT1 methylation, of HDAC 
target genes. Furthermore, 100 nM of panobinostat inhibited recruitment of SUV39H1 (a H3K9 
methyltransferase) and HP1α (a transcriptional repressor of ESR1) to the ESR1 promoter, 
compared to vehicle treated MDA-MB-231 cells 24 h post-treatment. Together this data 
suggests panobinostat mediated inhibition of SUV39H1 and HDAC1/DNMT1 and their 
associated methylation activity impaired the binding of HP1α to ESR1, ultimately releasing 
transcriptional repression of ESR1 resulting in re-expression of the ER at the protein level in 
TNBC cells in vitro.  
 
1.4.1.4 Jay Amin Hydroxamic Acid 
More recently, Librizzi et al., (2015) investigated the efficacy of a ferrocene hydroxamate 
derivative, N1-(ferrocenyl)-N8-hydroxyoctanediamide (JAHA), in TNBC in vitro. The 
cytotoxicity of JAHA was reported to be EC50 8.45 μM in MDA-MB-231 cells. Cell cycle 
analysis showed that 8.45 μM of JAHA increased the proportion of sub-G0 cell, 12% consistent 
with cytotoxicity, and was also found to increase the proportion of MDA-MB-231 cells in G2 
by 7.2% 48 h post-treatment as compared to vehicle control (Table 1.2). Interestingly, a 
subsequent Annexin-V flow cytometric study showed that 8.45 μM of JAHA caused a 216% 
increase in the proportion of non-apoptotic or necrotic MDA-MB-231 cells, whereas no 
significant change was seen in the proportion of apoptotic cells, compared to the vehicle control 
48 h post-treatment. To then clarify this finding changes in the mitochondrial membrane 
potential were investigated using a JC-1 Dye probe. Results showed that 8.45 μM of JAHA 
increased the proportion of MDA-MB-231 cells with an abrogated mitochondrial membrane 
potential by 31% as compared to the vehicle control after 48 h, suggesting cytotoxicity to 
perhaps occur through the intrinsic apoptotic cascade. Modulation of mitochondrial 
metabolism was then shown to be partially due to JAHA mediated induction of reactive oxygen 
species, where MDA-MB-231 cells treated with 8.45 μM of JAHA and 50 μM of anti-oxidant 
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butylated hydroxytoluene had 50% higher cell viability compared to cells treated with 8.45 μM 
of JAHA alone (Librizzi et al., 2015). Together this data appears to indicate that JAHA induces 
G2/M-phase arrest followed by necrosis in the majority of MDA-MB-231 cells undergoing cell 
death, whereas the minority of cells undergo cell death mediated by the intrinsic apoptotic 
cascade. Given the slightly lower potency of JAHA compared to other HDACis such as 
vorinostat, dacinostat, and panobinostat, and that in patients with TNBC the presence of 
necrosis is associated with significantly shorter disease free survival (HR 0.26, 95% CI 0.01-
0.50; Pistelli et al., 2013) further modifications to the capping group of JAHA should be 
investigated before in vivo trials are conducted. 
 
1.4.2 Hydroxythiopyridone Derivatives 
Chelation to Zn2+ is crucial for HDAC inhibition, where hydroxamate derivatives have shown 
great affinity for HDACs with IC50 values ranging 0.18 × 10-3 to 60 μM (Zangi et al., 2017). 
However, the hydroxamate group is able to chelate other metals including Fe2+, Cu2+, and Ni2+ 
with affinities exceeding that of Zn2+ leading to off target effects which can be avoided through 
the use of moieties more specific to Zn2+. This has led to research groups replacing the 
hydroxamic acid group with alternative chemical moieties such as a hydroxythiopyridone 
group. 
 
1.4.2.1 3-Hydroxypyridin-2-Thione Derivatives 
To explore alternative Zn2+ chelating groups Patil et al., (2013) investigated the use of 3-
hydroxypyridin-2-thione as a novel Zn2+ binding group for selective HDAC inhibition. Initial 
in silico molecular docking studies using Autodock 4.2 showed 3-hydroxypyridin-2-thione, 3-
hydroxypyridin-4-thione, and 1-hydroxypyridin-2-thione groups are potentially able to bind 
Zn2+ at the active site of HDAC1, 6, and 8, suggesting hydroxypyridone may serve as an 
HDACi Zn2+ chelator. Specifically, the research group determined 3-hydroxypyridin-2-thione 
to have an IC50 of 681 ± 11 nM against HDAC6 and 3675 ± 1201 nM against HDAC8 but no 
effect on HDAC1 likely due to the relatively narrow tunnel leading to the HDAC1 active site 
compared to HDAC6 and HDAC8. Based on the efficacy of 3-hydroxypyridin-2-thione the 
derivative 1-benzyl-3-hydroxypyridin-2-thione was synthesised and found to have greater 
inhibitory potency in HDAC8, IC50 1272 ± 200 nM, though no changes in HDAC1 or HDAC6 
inhibition were reported, likely due to the inability of the phenyl group to form hydrogen bonds 
at the entrance of the HDAC6 active site. To further enhance HDAC affinity of 
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hydroxythiopyridone derivatives, a screen for biphenyl derivatives of 3-hydroxypyridin-2-
thione was performed. The compound 1-(2-ethyl-(1,1′-biphenylmethyl))-3-
hydroxyoxypyridin-2-thione was found to have the greatest potency against HDAC6 IC50  
306 ± 69 nM (HDAC8 IC50 3105 ± 1649 nM) and the compound 1-(4-methyl-(1,1′-
biphenylmethyl))-3-hydroxyoxypyridin-2-thione the greatest potency against HDAC8 with an 
IC50 of 800 ± 304 nM (HDAC6 IC50 454 ± 42 nM). The biphenyl derivatives synthesised were 
hypothesised to have no effect on HDAC1 due to their greater affinity for the substrate binding 
pocket as opposed to the HDAC active site preventing Zn2+ chelation from occurring. 
Interestingly, biphenyl derivatives of hydroxypyridin-2-thione lacking the thione group, which 
have greater resemblance to the hydroxamate Zn2+ binding moiety completely lacked HDAC1, 
6, and 8 inhibitory activity at concentrations <10 μM (Patil et al., 2013).  This is likely a result 
of the electron withdrawing effect of the pyridine group preventing nitrogen from seating at 
the base of the active site and instead seating within the tunnel leading to the active site 
sterically preventing Zn2+ chelation. Then looking at derivative efficacy in vitro 1-(2-methyl-
(1,1′-biphenylmethyl))-3-hydroxyoxypyridin-2-thione was found to have the greatest 
cytotoxicity in the three neoplastic cell lines assayed DU-145, LNCaP, and Jurkat with an EC50 
of 13.59 μM, 7.75 μM, and 3.19 μM, respectively (Table 1.2). However, despite showing 
potent HDAC inhibition at the nanomolar level vorinostat was found to display more potent 
HDAC inhibition and cytotoxicity than the derivatives investigated, indicating further 
investigations into hydroxypyridone analogues need to be performed. 
 
A subsequent study performed by Sodji et al., (2013) looked at the structure activity 
relationships of modulating hydroxythiopyridone linker length on HDAC1, 6, and 8 inhibition. 
The linker pharmacophore acts to optimise the distance from the Zn2+ ion to the outer rim 
amino acids to enhance HDACi affinity and stability at the active site. The ability of  
3-hydroxypyridin-2-thione derivatives with one (1-phenyltriazolylethyl-3-hydroxypyridin-2-
thione) to six (1-phenyltriazolylheptyl-3-hydroxypyridin-2-thione) linker –CH2 methylene 
groups to inhibit HDAC1, 6, and 8 were investigated using self-assembled monolayer 
desorption ionisation mass spectrometry. Five linker groups was found to be the optimal length 
to inhibit HDAC6 (IC50 911 ± 173 nM) and HDAC8 (IC50 917 ± 139 nM) activity, which was 
shown to occur as a result of stabilising π-stacking between the phenyl ring and Phe-680 
located adjacent to the active site on HDAC6 and insertion of the phenyl ring into a solvent 
inaccessible hydrophobic pocket adjacent to the active site of HDAC8 stabilising HDACi 
binding. In concordance with the previous study, the hydroxypyridone derivatives studied were 
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found to have no HDAC1 inhibitory activity. To then further optimise HDAC inhibition the 
authors investigated the structure activity relationship of adding phenyl ring substituents to 1-
phenyltriazolylpentyl-3-hydroxypyridin-2-thione, the five –CH2 methylene linker HDACi. The 
addition of a meta position cyan group yielded the most potent HDAC6 inhibitor (IC50 356 ± 
72 nM), though this compound displayed poor HDAC8 inhibition (IC50 356 ± 72 nM; Sodji et 
al., 2013). Molecular docking studies revealed the compound to display great HDAC6 potency 
because the cyano group is ideally positioned to form stabilising hydrogen bonds with Ser-568 
proximal to the HDAC6 active site, whereas the active site of HDAC8 has a restrictive size 
limitation owing to its smaller volume, hence the addition of bulky functional groups to the 
phenyl ring impairs Zn2+ binding group access to the active site (Sodji et al., 2013). Subsequent 
in vitro investigations revealed that 1-(3-benzonitrile)triazolylpentyl-3-hydroxypyridin-2-
thione displayed the greatest cytotoxic potency in DU-145, LNCaP, and Jurkat cells with an 
EC50 of 5.03 μM, 3.49 μM, and 3.44 μM, respectively (Table 1.2). However, as with the 
previous study, vorinostat was found to display more potent HDAC inhibition and cytotoxicity 
in the three neoplastic cell lines investigated, suggesting further hydroxythiopyridone 
pharmacophore optimisation is required.  
 
To build upon the HDAC inhibitory potential of hydroxythiopyridone derivatives Muthyala 
et al., (2015) investigated the inhibitory activity of 1-hydroxypyridine-2-thiones against 
HDACs. The novel HDACis were found to have poor inhibitory activity against class IIb and 
IV HDACs compared to vorinostat, however were more efficacious against class IIa HDACs. 
The parent compound 1-hydroxy-6-thioxo-1,6-dihydropyridine-2-carboxylic acid was found 
to have an IC50 of 71 μM, 35 μM, 29 μM, 47 μM, and 3.3 μM against HDAC4, 5, 7, 9, and 8, 
respectively, but displayed poor HDAC active site selectivity, calculated as IC50max/IC50min. 
The derivative 2-(1-hydroxy-6-thioxo-1,6-dihydropyridine-2-carboxamido)-2-phenylacetic 
acid was found to produce the greatest increase in HDAC inhibition potency with IC50 values 
of 64 μM, 27 μM, 49 μM, 34 μM, and 1.2 μM against HDAC4, 5, 7, 9, and 8, respectively, 
which correlated with an 8.3-fold increase in class IIa HDAC selectivity over its parent 
compound. Moreover, substitution of the bulky phenyl group adjacent to the Zn2+ binding 
pharmacophore for a more compact methyl group forming 1-hydroxy-6-thioxo-1,6-
dihydropyridine-2-carbonyl-alanine was found to promote inhibitory activity against HDAC8 
specifically (IC50 0.93 μM), likely owing to the smaller active site of HDAC8 established by 
Sodji et al., (2013). A follow up in silico molecular docking study was performed on the 
hydroxythiopyridone derivatives at the active site of HDAC8 using the Schrodinger Modelling 
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Package to determine if this hypothesis was true. Docking studies showed that the terminal 
carboxylate of the methyl derivative is able to form stabilising hydrogen bonds with the Zn2+ 
chelating residue His-180 at the HDAC8 active site, whereas hydrogen bonding did not occur 
in the phenyl derivative due to the bulky nature of the aromatic side chain. Subsequent in vitro 
investigations in leukaemia cell lines revealed that the methyl hydroxythiopyridone derivative 
had greater cytotoxic potency than vorinostat. The cytotoxicity of the methyl derivative was 
found to be EC50 3.7 μM, 25 μM, and 76 μM, in K562, U937, and HEK293 cells, respectively, 
compared to 38 μM, 100 μM, and 100 μM reported with vorinostat (Table 1.2; Muthyala et 
al., 2015). Together this data provides evidence of the efficacy and potency of 
hydroxythiopyridone derivatives as HDACis and the need to explore alternative Zn2+ binding 
groups. 
 
1.5 Aims of Current Research 
HDACis are an emerging class of chemically heterogeneous anticancer agents that promote 
a relaxed and hyperacetylated chromatin structure leading to re-expression of silenced tumour 
suppressor genes and modulation of the Hsp90 and NF-κB p65 signalling pathways, which 
ultimately induce cell cycle arrest and apoptosis of TNBC cells. HDACis are classified into 
different categories based on their pharmacophores, and the implication of this molecular 
diversity is that the precise mechanism by which these compounds work is still poorly 
understood. Vorinostat is a prototypical HDACi which was approved in 2006 by the Food and 
Drug Administration for the treatment of cutaneous T-cell lymphoma, and has been subjected 
to chemical manipulation of its core structure to enhance its HDAC inhibitory and cytotoxic 
effect on breast cancer cells (Mann et al., 2007). TNBC cells lack expression of the ER, PR, 
and HER2 receptors and are thus poorly responsive to hormonal and HER2-targeted therapies, 
reflected by the cohort’s poorer clinical outcomes compared to other breast cancer types (Ye 
et al., 2016). Based on these reports the current project aimed to investigate the cytotoxicity 
and mechanisms of action of a novel hydroxamate derivative Jazz-90 (N1-hydroxy-N8-(4-
(pyridine-2-carbothioamido)phenyl)octanediamide) alongside vorinostat, and two 
hydroxythiopyridone derivatives M1S (1-benzyl-3-hydroxy-2-methylpyridine-4(1H)-thione) 
and M2S (3-hydroxy-2-methyl-1-phenethylpyridine-4(1H)-thione) in TNBC cells in vitro  
(Fig 1.3). The realisation of this project was made possible thanks to a collaboration with Dr. 
Muhammad Hanif of the Faculty of Science, University of Auckland, New Zealand, who 
kindly provided Jazz-90, vorinostat, M1S, and M2S.  
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1.5.1 Preliminary Data Supporting Jazz-90, M1S, and M2S  
Novel HDACis Jazz-90, and M1S and M2S have been synthesised based on the structures 
the vorinostat and hydroxythiopyridone, respectively. Preliminary unpublished data generated 
by Muhammad Hanif (personal communication, 2018) has shown the derivatives to exhibit 
potent anticancer cytotoxicity in in vitro models of cervical, colon, lung, and colorectal 
carcinoma (Table 1.3). A hypothesis for the current project is that the HDACi derivatives will 
produce similar potent cytotoxic effects in in vitro models of TNBC. 
 
1.5.2 Hypothesis and Objectives 
Jazz-90, vorinostat, M1S, and M2S will exhibit cytotoxic EC50 concentrations at 
micromolar concentrations, induce a significant increase in acetylated histone-H3 protein 
expression, and significantly downregulate cyclin, p53, Hsp90, and NF-κB p65 protein 
expression in TNBC cells in vitro. 
 
The following objectives will address this hypothesis: 
A) To assess the cytotoxicity of Jazz-90, vorinostat, M1S, and M2S, MDA-MB-231 and 
MDA-MB-468 cells will be treated with titrated concentrations of the four compounds. 
B) To determine HDAC inhibitory potency, changes in acetylated histone-H3 protein 
expression will be analysed by Western blotting in the two TNBC cell lines. 
C) Changes in cyclin E2, cyclin B1, cyclin D1, and p53 protein expression will be 
investigated using Western blotting in the two TNBC cell lines. 
D) Changes in Hsp90 and NF-κB p65 protein expression will be determined by Western 




Table 1.3 Preliminary Evidence of the Cytotoxic Potency of Jazz-90, M1S, and M2S in 




MDA-MB-231 and MDA-MB-468 breast cancer cells were purchased from the American 
Type Culture Collection (ATCC, Manassas, VA, USA). Plastic tissue culture flasks, 96-well 
plates, and 10 cm petri dishes were purchased from Corning (Corning, NY, USA). Glutamine, 
sulforhodamine B (SRB) salt, trypsin, 100% methanol, 0.1% ponceau red stain, dimethyl 
sulfoxide (DMSO), TWEEN-20, Whatman blotting paper, microcentrifuge tubes, Complete™ 
Protease Inhibitor Cocktail, cell lysis buffer, tris-base, bovine insulin, copper sulphate, sodium 
orthovanadate, sodium pyrophosphate, sodium fluoride, hydrochloric acid, sodium hydroxide, 
methanol, glucose, penicillin, streptomycin, tris-hydrochloride, trizma base, glycine, 
deoxycholate, Igepal, glycerol, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
tetramethylethylenediamine, sodium azide and Protease Inhibitor Cocktail Set III were 
purchased from Sigma-Aldrich (Sigma-Aldrich, MO, USA). Dulbecco’s modified eagle’s 
medium nutrient mixture F-12, conical centrifuge tubes, phosphate-buffered saline (PBS), 
0.25% trypsin-EDTA, EGTA, phenylmethylsulfonyl fluoride, bicinchoninic acid kit, reducing 
agent, SeeBlue® Plus2 Protein Ladder, SuperSignal West Pico Chemiluminescent Substrate, 
and sodium pyruvate were purchased from Thermo-Fisher Scientific (Thermo Fisher 
Scientific, MA, USA). Molecular weight markers, acetylated histone-H3, cyclin E2, cyclin B1, 
cyclin D1, NF-κB p65, Hsp90, p53, β-tubulin and β-actin primary antibody was purchased 
from Cell Signalling Technology (Cell Signalling Technology, MA, USA). Acrylamide, 
bisacrylamide, polyvinylidene difluoride (PVDF) membrane, goat anti-rabbit and goat anti-
mouse secondary antibodies, and sodium dodecylsulfate (SDS) were purchased from Bio-Rad 
Laboratories (Hercules, CA, USA). Ethanol (96%) was purchased from Scharlau (Spain). 
Trichloroacetic acid (TCA) was purchased from (Merck, Germany). Foetal bovine serum 
(FBS) was purchased from Moregate (New Zealand). Jazz-90, vorinostat, M1S, and M2S 
analogues were synthesised by Dr. Muhammad Hanif from the University of Auckland, Faculty 






2.2 Cell Culture Conditions 
MDA-MB-231 and MDA-MB-468 cells were grown in 75 cm2 or 175 cm2 cell culture flasks 
at 37°C and 5% CO2 in a humidified environment. Cells were grown in Dulbecco’s modified 
eagle’s medium nutrient mixture F-12 9% FBS 1% penicillin-streptomycin 1% glutamine 
media and passaged according to manufacturer recommendation, with a media change 
performed every three days to maintain adequate nutrients.  
 
Cell lines were passaged every 3-5 days or when they were approximately 85% confluent. 
During passaging media was aspirated off and cells washed with 37°C PBS solution to remove 
α1-antitrypsin found in FBS. Cells were then detached from the flask with 0.25% trypsin-
EDTA. Detached cells were re-suspended in media. Cells were then seeded into new flasks 
typically at a density of 80,000 cells/mL. 
 
2.3 Sulforhodamine B Cytotoxicity Assay 
The SRB assay was carried out as described by Skehan et al., (1990). MDA-MB-231 and 
MDA-MB-468 cells were seeded into 96-well plates at 8000 cells/well and 15,000 cells/well, 
respectively, to achieve 90% confluence after a 24 h incubation period during which time cells 
would adhere to the plastic cell culture dish. Cells would be then treated with titrating amounts 
of Jazz-90, vorinostat, M1S, and M2S over a period of 72 h. Vehicle control cells were treated 
with 0.75% DMSO equal to DMSO concentration in drug treated groups. At the end of the 
treatment period media was aspirated off and remaining viable cells fixed with 100 μL of 10% 
TCA solution. 96-well plates were then left at 4°C until stained. Plates were then rinsed with 
distilled water, air-dried to remove water residue, then cells stained with 100 μL of 0.4% SRB 
solution (in 1% acetic acid). Unbound excess SRB stain was then aspirated and the remaining 
residue washed off with 1% acetic acid solution, followed by air-drying. After drying, 150 μL 
of 10 mM Tris base (pH 10.5) was added to each well and left for 10 min to solubilise SRB 
dye within cells. The absorbance of each well was then read at 510 nm using a Spectramax 
Plus plate reader and absorbance values interpolated using a linear standard curve generated 
with known absorbances of 0-50,000 cells in order to determine the number of viable cells 
following drug treatment. 
 
Cytotoxicity time-course assays were performed by treating MDA-MB-231 and  
MDA-MB-468 cells with one-fold (1X) and four-fold (4X) the cytotoxic EC50 concentration 
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for a period of 12, 36, 48, and 72 h. 0.75% DMSO served as a control analogous to DMSO 
concentration in drug treated groups.  
 
2.4 SDS-PAGE and Western Blotting Analysis 
 
2.4.1 Whole Cellular Lysate Protein Preparation and Harvesting 
MDA-MB-231 and MDA-MB-468 cells were seeded at a density of 1.0 × 106 cells/dish in  
10 cm cell culture dishes in 10 mL of complete media, followed by a 24 h incubation period. 
Cells were then treated with 1X and 4X the EC50 concentration derived from the SRB assay (to 
prevent changes in protein expression to be confounded by drug cytotoxicity), 0.75% DMSO 
control, or with 1 mL of media lacking FBS (untreated) for 24 h.  
 
After the treatment period dishes were placed on ice and media aspirated followed by a 4°C  
5 mL PBS wash. Next, cells were treated with 75 μL of lysis buffer (50 mM Tris base (pH 7.5), 
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% SDS, 0.5% NP-40, 10 mM sodium fluoride, 
1 mM sodium orthovanadate, 0.1 mM phenylmethylsulfonyl fluoride, 1 mM sodium 
pyrophosphate, and complete protease inhibitor cocktail tablets) to break apart cell membranes 
and expose protein. Dishes were then incubated on ice for 10 min, mechanically detached using 
a cell scraper, and ~400 μL of cellular lysate was transferred to a 1.5 mL Eppendorf tube. The 
lysate was then sonicated at 30% amplitude for 3 × 7 seconds followed by centrifugation at 
14,000 rpm for 10 min at 4°C and the remaining supernatant containing protein transferred to 
another Eppendorf tube for storage at -80°C. 
 
2.4.2 Nuclear Protein Preparation and Harvesting 
To determine changes in nuclear expression of Hsp90 and NF-κB p65, MDA-MB-468 cells 
were seeded into 10 cm cell culture dishes at a density of 2.0 × 106 cells/dish in 10 mL of 
complete media, followed by a 24 h incubation period. Cells were then treated with 1X and 4X 
the EC50 concentration derived from the SRB assay, 0.75% DMSO control, or 1 mL of 
starvation media lacking FBS.  
 
After the treatment period, dishes were placed on ice and media aspirated followed by a 4°C  
5 mL PBS wash. Next, cells were treated with 1.5 mL of sterile 4°C PBS, detached using a cell 
scraper, and transferred to a 1.5 mL Eppendorf tube. Samples were then centrifuged at  
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1000 rpm for 5 min followed by re-suspension in 150 μL of cell membrane lysing buffer  
(10 mM HEPES (pH 7.8), 10 mM KCl, 0.1 mM EDTA). Samples were then left overnight at  
-80°C. The following day, samples were thawed then homogenised using a Wheaton 0.2 mL 
Micro Tissue Grinder Set. Samples were then centrifuged at 1000 rpm for 5 min at 4°C and the 
supernatant containing the cytosolic fraction transferred to a 1.5 mL Eppendorf tube for storage 
at -80°C.  
 
The remaining pellet was re-suspended in a PBS-protease inhibitor cocktail (2 mM NaF, 2 
mM sodium orthovanadate, 0.1 mM phenylmethylsulfonyl fluoride in ethanol, 1 mM sodium 
pyrophosphate, protease inhibitor cocktail set III). Samples were then centrifuged at 1000 rpm 
for 5 min at 4°C and the resulting supernatant discarded. The remaining pellets were  
re-suspended in 50 μL of nuclear membrane lysing buffer (2 mM HEPES (pH 7.8), 400 mM 
KCl, 1 mM EDTA, 10% glycerol) and stored overnight at -80°C. The following day, samples 
were thawed and sonicated at 30% amplitude for 3 × 7 seconds followed by centrifugation at 
12,000 rpm for 10 min at 4°C. The remaining supernatant containing the nuclear fraction was 
transferred to a 1.5 mL Eppendorf tube for storage at -80°C.  
 
2.4.3 Protien Standardisation using the Bicinchoninic Acid Assay 
2 μL of protein lysate per treatment group was added to a flat bottom 96-well plate in 
triplicate. The 4,4’-dicarboxy-2,2’-biquinoline (BCA) solution was prepared by mixing BCA 
and 4% CuSO4.5H2O in a 50:1 ratio, followed by the addition of 200 μL to each well and 
incubation at 37°C for 30 min. A standard range of 0-500 μg/μL of protein was prepared and 
used to interpolate the unknown protein concentration of cellular lysates. Absorbance at 562 
nm was determined using a Bio-Rad Benchmark Plus microplate reader and Microplate 
Manager Software 5.2.1. Protein lysates were then standardised to 100 μg/μL by diluting in 
lysis buffer and β-mercaptoethanol. Samples were then heated to 95°C for 5 min before being 
stored at -20°C for further investigation. Samples were used within 2 weeks of storage.  
 
2.4.4 Sodium Dodecylsulfate-Polyacrylamide Gel Electrophoresis 
SDS gel electrophoresis was used to resolve proteins based on molecular weight. Each gel 
consisted of an upper stacking gel (0.43 mL acrylamide/bisacrylamide solution (29:1),  
0.63 mL upper Tris HCl buffer, 25 μL 10% ammonium persulfate, 1.45 mL dH2O, 1.25 μL 
tetramethylethylenediamine) and lower resolving gel. Two types of of resolving gels were used 
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in the study: to analyse proteins >25 kDa a 10% gel was used (2.5 mL 
acrylamide/bisacrylamide solution (29:1), 1.88 mL lower Tris HCl buffer, 250 µL  
50% glycerol, 37.5 µL 10% ammonium persulfate, 2.83 mL dH2O, 5 µL 
tetramethylethylenediamine) and ≤25 kDa 15% gels was used (3.75 mL 
acrylamide/bisacrylamide solution (29:1), 1.88 mL lower trisaminomethane buffer, 300 µL 
50% glycerol, 37.5 µL 10% ammonium persulfate, 1.55 mL dH2O, 5 µL 
tetramethylethylenediamine). 
 
A molecular weight marker was loaded into the first well and 10 μL of sample loaded into 
each additional well, with β-mercaptoethanol sample buffer (4% SDS, 20% glycerol, 10%  
β-mercaptoethanol, 0.004% bromphenol blue, 0.125 M Tris HCl, pH 6.8) being loaded into 
empty wells to ensure lanes migrate in parallel. Gels were first run at 80 cV in running buffer 
solution (25 mM Tris-base, pH 8.3, 0.192 M glycine, 0.1% (w/v) SDS) with a Bio-Rad Power 
Pac 200 and Bio-Rad Mini-Protean III apparatus until the blue β-mercaptoethanol solution had 
migrated to the end of the stacking gel (~20 min), after which the voltage was increased to  
110 cV until the dye the front had reached the end of the resolving gel (~80 min). 
 
2.4.5 Wet Transfer to Polyvinylidene Difluoride Membrane 
To transfer sorted protein samples from the SDS-PAGE gel to a PVDF membrane for 
probing, a voltage is applied across the gel (cathode side) and membrane (anode side) in 
transfer buffer solution (25 mM Tris-base, 0.192 M glycine, 10% methanol, pH 8.3). After 
removal of the SDS-PAGE gel from the running tank the gel was equilibrated in transfer buffer 
solution to remove excess SDS. Prior to transfer, the PVDF membrane was activated in 100% 
methanol for 1 min, rinsed with dH2O for 1 min, then equilibrated in transfer buffer for 10 min. 
Proteins were then transferred for 1.5 h at 100 cV using the Bio-Rad wet transfer system. 
 
2.4.6 Western Blotting 
Western blotting was conducted according to the General Protocol for Western Blotting (Bio-
Rad Laboratories Inc., Hercules, CA, USA; General Protocol for Western Blotting, 2018). 
After the wet transfer was complete, PVDF membranes were washed with ddH2O followed by 
incubation in blocking buffer (5% bovine serum albumin (BSA), 1% sodium azide) for 1 h at 
room temperature to inhibit non-specific antibody binding. Membranes were then washed with 
tris buffered saline (0.025 mM Tris-base, 0.1 M NaCl, pH 7.4; TBS) and incubated with 
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primary antibody solution diluted in 5% BSA overnight at 4°C. Primary antibody solution was 
then removed for re-use and the membranes washed with 10 mL of TBS-Tween20 solution 
(0.05% Tween-20, 0.025 mM Tris-base, 0.1 M NaCl, pH 7.4) six times for 5 min each to 
remove non-specific primary antibody binding. Membranes were then incubated in 5% non-fat 
milk/TBS with horseradish-peroxidase conjugated goat anti-mouse or goat anti-rabbit 
secondary antibody at room temperature for 1 h. Secondary antibody was then discarded and 
the PVDF membrane washed with 10 mL of TBS-Tween solution six times for 5 min each.  
Protein bands were then visualised by treating membranes with SuperSingnal West Pico 
Chemiluminescent Substrate then capturing 428 nm photos of light produced by the 
chemiluminescent oxidation of luminol by horseradish-peroxidase on Thermo Scientific  
CL-XPosure Film. Digital chemiluminescent images were taken using a Bio-Rad Versadoc 
Imaging System and quantified based on protein band optical density using Bio-Rad Quantity 
One software (version 4.6.8). Each Western blot was performed in triplicate.  
 
2.5 Statistical Analysis 
Statistical analysis was performed using Prism 7 and the mean values ± standard error of the 
mean (SEM) for each set of triplicate experiments were plotted. Data from the SRB assay was 
analysed using non-linear regression and the EC50 value calculated as  
EC50 = Minimum Cell Viability (%) + (Maximum Cell Viability (%) - Minimum Cell Viability 
(%))/(1 + 10(Log10EC50 – Log10DrugConcentration)×HillSlope). Data from time-course cytotoxicity assays 
were analysed using a two-way ANOVA (parameters time and treatment group) with a 
Bonferroni’s post-hoc test to test for statistical significance between the vehicle 0.75% DMSO 
and various treatment groups at the various time points (α=0.05). Data from Western blots was 
analysed using a one-way ANOVA with a Bonferroni’s post-hoc test to test for statistical 











3.1.1 Dose Response Cytotoxicity of Vorinostat, Jazz-90, M1S, and M2S 
To assess the cytotoxic potency of vorinostat, Jazz-90, M1S, and M2S towards TNBC cell 
lines, MDA-MB-231 and MDA-MB-468 cells were treated with titrating concentrations of 
each compound independently. 
 Jazz-90 and vorinostat showed similar cytotoxic potency in MDA-MB-231 cells, with Jazz-
90 producing an EC50 value of 1.41 ± 1.14 μM (95% CI, 1.06-2.22 μM; Fig 3.1A) and 
vorinostat 2.10 ± 1.06 μM (95% CI, 1.88-2.34 μM; Fig 3.1B). This was also seen in the  
MDA-MB-468 cell line, with Jazz-90 producing an EC50 of 5.23 ± 1.11 μM (95% CI, 4.24-
6.45 μM; Fig 3C) and vorinostat 5.21 ± 1.11 μM (95% CI, 4.21-6.38 μM; Fig 3.1D). 
Figure 3.1 Cytotoxicity of Jazz-90 and vorinostat in MDA-MB-231 and MDA-MB-468 cell lines 
MDA-MB-231 cells were seeded in 96-well plates at 8 × 103 cells/well and incubated for 24 h at 37°C. Cells were treated 
with A) 0.20-6.8 μM of Jazz-90 and B) 0.015-150 μM of vorinostat for 72 h. MDA-MB-468 cells were seeded in 96-well 
plates at 15 × 103 cells/well and incubated for 24 h at 37°C. Cells were treated with C) 0.0625-150 μM of Jazz-90 and  
D) 0.015-150 μM of vorinostat for 72 h. Vehicle control cells were treated with 0.75% DMSO. At the end of the treatment 
period cell viability was determined with a SRB assay. Results expressed as cell viability (% control) ± SEM from at least 
3 independent experiments conducted in at least triplicate. EC50 values attained using non-linear regression:  
EC50 = Minimum Cell Viability (%) + (Maximum Cell Viability (%) - Minimum Cell Viability (%))/(1 + 10(Log10EC50 – 
Log10DrugConcentration)×HillSlope). 
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M1S and M2S showed similar cytotoxicity in MDA-MB-231 cells, with M1S producing an 
EC50 of 2.78 ± 1.04 μM (95% CI, 2.54-3.04 μM; Fig 3.2A) and M2S 2.63 ± 1.04 μM (95% CI, 
2.44-2.84 μM; Fig 3.2B). In MDA-MB-468 cells, M1S was slightly more potent,  
EC50 1.66 ± 1.09 μM (95% CI, 1.38 - 2.04 μM; Fig 3.2C) than M2S EC50 4.29 ± 1.29 μM (95% 
CI, 2.58 - 9.14 μM; Fig 3.2D), however the cytotoxicity of M1S plateaued at 35% cell viability 
between 5-20 μM. 
 
 
3.1.2 Time-course Cytotoxicity Studies 
To determine if vorinostat, Jazz-90, M1S, and M2S produced a cytostatic or cytotoxic effect, 
MDA-MB-231 and MDA-MB-468 cells were treated with 1X and 4X the EC50 concentration 
Figure 3.2 Cytotoxic EC50 determination of M1S and M2S in MDA-MB-231 and MDA-MB-468 cell lines 
MDA-MB-231 cells were seeded in 96-well plates at 8 × 103 cells/well and incubated for 24 h at 37°C. Cells were treated 
with A) 0.50-20 μM of M1S and B) 0.50-20 μM of M2S for 72 h. MDA-MB-468 cells were seeded in 96-well plates at  
15 × 103 cells/well and incubated for 24 h at 37°C. Cells were treated with C) 0.10-20 μM of M1S and D) 0.05-100 μM of 
M2S. Vehicle control cells were treated with 0.75% DMSO. At the end of the treatment period cell viability was determined 
with a SRB assay. Results expressed as cell viability (% control) ± SEM from at least 3 independent experiments conducted 
in at least triplicate. EC50 values attained using non-linear regression: EC50 = Minimum Cell Viability (%) + (Maximum Cell 
Viability (%) - Minimum Cell Viability (%))/(1 + 10(Log10EC50 – Log10DrugConcentration)×HillSlope). 
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followed by SRB staining to determine changes in cell number over time. Time-,  
concentration-, and cell line-dependent effects were observed followed drug treatment. There 
was no statistically significant difference between untreated MDA-MB-231 or MDA-MB-468 
cells and 0.75% DMSO treated cells at 12, 24, 36, 48, 60, or 72 h post-treatment. 
 
The EC50 of vorinostat and M2S significantly decreased the proportion of viable  
MDA-MB-231 cells by 51.6% and 67.1% compared to DMSO control, respectively, 24 h  
post-treatment (Fig 3.3A). 1X the EC50 of Jazz-90 and M1S were found to cause a significant 
decrease in cell number after 60 h, decreasing the proportion of viable MDA-MB-231 cells by 
70.3% and 52.7%, respectively, compared to control. In MDA-MB-468 cells, M2S was found 
to induce a significant decrease in cell viability at the earliest time-point among the four 
compounds (Fig 3.3B). After a treatment period of 24 h, 1X of M2S significantly reduced the 
proportion of viable MDA-MB-468 cells 77.8%, which was followed by 1X EC50 of vorinostat 
at 36 h, which reduced cell viability by 49.7% compared to control. 1X the EC50 of Jazz-90 
and M1S induced a significant decrease in cell viability 12 h earlier in MDA-MB-468 cells 
compared to MDA-MB-231 cells, where 48 h post-treatment the compounds reduced the 
proportion of viable cells by 53.4% and 37.4%, respectively, compared to control. 
Interestingly, in all four treatment groups the proportion of viable MDA-MB-231 cells 
decreased from 12-24 h post-treatment followed by a similar rate of proliferation between 24-
48 h as the control, which was not seen in MDA-MB-468 cells.  
 
4X the EC50 concentration of M1S and M2S significantly reduced the proportion of viable 
MDA-MB-231 cells by 91.3% and 97.3%, respectively, 12 h post-treatment, which was 
followed by vorinostat at 24 h post-treatment, which reduced the proportion of viable cells by 
55.6% compared to control (Fig 3.3C). Jazz-90 was the slowest acting compound in terms of 
cytotoxicity in MDA-MB-231 cells and was found to significantly reduce the proportion of 
viable cells only after 36 h of exposure which was by 82.0% as compared to control. In  
MDA-MB-468 cells no significant cell death occurred in the first 12 h of 4X EC50 drug 
treatment, indicating reduced or slower activation of cytotoxic mediators in this TNBC subtype 
compared to MDA-MB-231 cells. As was seen in MDA-MB-231 cells the 
hydroxythiopyridone derivatives M1S and M2S induced significant cytotoxicity earlier than 
the hydroxamate derivatives, with 4X the EC50 of M1S and M2S reducing MDA-MB-468 cell 
viability by 80.1% and 63.7% 24 h post-treatment in comparison to control (Fig 3.3D). 4X of 
Jazz-90 and vorinostat were then found to induce a significant decrease in the proportion of  
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Figure 3.3 Time-course cytotoxicity in MDA-MB-231 and MDA-MB-468 cells 
A) MDA-MB-231 cells were seeded in 96-well plates at 8 × 103 cells/well and incubated for 24 h at 37°C.  
MDA-MB-231 were treated with The EC50 concentration of Jazz-90 (1.41 μM), vorinostat (2.10 μM), M1S (2.78 μM), or 
M2S (2.63 μM) for 12-72 h. B) MDA-MB-468 cells were seeded in 96-well plates at 15 ×  103 cells/well and incubated 
for 24 h at 37°C. MDA-MB-468 cells were treated with The EC50 concentration of Jazz-90 (5.23 μM), vorinostat  
(2.10 μM), M1S (1.66 μM), or M2S (4.29 μM) for 12-72 h. C) MDA-MB-231 cells were treated with 4X the EC50 
concentration of Jazz-90 (5.63 μM), vorinostat (8.53 μM), M1S (11.14 μM), or M2S (10.52 μM) for 12-72 h. D)  
MDA-MB-468 cells were treated with 4X the EC50 concentration of Jazz-90 (20.92 μM), vorinostat (20.83 μM), M1S 
(6.66 μM), or M2S (17.17 μM) for 12-72 h. Vehicle control cells were treated with 0.75% DMSO. At the end of each 
treatment period, the cell number was determined using a SRB assay. Results are expressed as cell number ± SEM from 
3 independent experiment performed in triplicate. Data was analysed using a two-way ANOVA coupled with a Bonferroni 
post-hoc test. ☉ Jazz-90, x vorinostat, * M1S, + M2S significantly different from control p < 0.05. 
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viable MDA-MB-468 cells 36 h post-treatment, where cell number was reduced by 51.4% and 
49.0% in comparison to control. 
 
Based on these results, changes in MDA-MB-231 and MDA-MB-468 protein expression 
were investigated after treatment with 1X and 4X the EC50 concentration for a period of 24 h. 
The treatment period was chosen as to look for changes in cell signalling and protein expression 
leading up to cell death. 
 
3.2 Acetylated Histone-H3  
To investigate the HDAC inhibition efficacy of the four compounds in TNBC cells, changes 
in acetylated histone-H3 were analysed using Western blotting.  
1X and 4X the EC50 concentration of Jazz-90 and vorinostat significantly increased the 
expression of acetylated histone-H3 in a dose-dependent manner in MDA-MB-231 cells, by 
1041% and 1306%, and 1472% and 1783%, respectively, 24 h post-treatment in comparison 
to vehicle control (Fig 3.4A). A similar but more profound effect was seen in MDA-MB-468 
cells where 1X and 4X the EC50 concentration of Jazz-90 and vorinostat significantly increased 
acetylated histone-H3 expression by 21040% and 41032%, and 49771% and 71971%, 
respectively, 24 h post-treatment in comparison to the vehicle control (Fig 3.4B). Uniquely, in 
MDA-MB-468 cells 4X the EC50 of M1S and M2S was found to significantly increase 
acetylated histone-H3 expression, by 11404% and 10795%, respectively, 24 h post-treatment 
compared to control. The significant increase in acetylated histone-H3 expression indicates 
Jazz-90, M1S, and M2S to act as HDACis in TNBC cells. 
 42 
 
3.3 Cyclin B1, Cyclin E2, and Cyclin D1  
To then determine possible mechanisms behind the cytostatic and cytotoxic effects of our 
novel HDACis, Western blotting was performed looking for changes in G2/M-phase regulator 
cyclin B1, G1/S-phase regulator cyclin E2, and a G1 progression regulator cyclin D1. The EC50 
and 4X the EC50 concentration of vorinostat significantly reduced protein expression of cyclin 
B1 in MDA-MB-231 cells by 64.8% and 65.4%, respectively, in comparison to vehicle control 
(Fig 3.5A). Only 1X the EC50 of M1S was found to significantly reduce cyclin B1 expression 
in MDA-MB-231 cells, which was by 68.3% below vehicle control, while 4X M2S was found 
to have no significant effect. These findings were not replicated in MDA-MB-468 cells, where 
none of the four compounds at 1X or 4X the EC50 concentration had a significant effect on 
cyclin B1 protein expression (Fig 3.5B). No significant change in cyclin E2 was observed in 
MDA-MB-231 cells after drug treatment with any of the four compounds  
Figure 3.4 Effect of Jazz-90, vorinostat, M1S, and M2S on acetylated histone-H3 in MDA-MB-231 and  
MDA-MB-468 cells 
MDA-MB-231 and MDA-MB-468 cells were seeded at 1.0 x 106 cells/dish in 10 cm cell culture dishes for 24 h at 37°C, 
independently. A) MDA-MB-231 cells were treated with 0.75% DMSO, 1X Jazz-90 (1.41 μM), 4X Jazz-90 (5.63 μM), 
1X vorinostat (2.10 μM), 4X vorinostat (8.40 μM), 1X M1S (2.78 μM), 4X M1S (11.14 μM), 1X M2S (2.63 μM), or 4X 
M2S (10.52 μM) for a period of 24 h. B) MDA-MB-468 cells were treated with 0.75% DMSO, 1X Jazz-90 (5.23 μM), 
4X Jazz-90 (20.92 μM), 1X vorinostat (5.21 μM), 4X vorinostat (20.83 μM), 1X M1S (1.67 μM), 4X M1S (6.66 μM), 1X 
M2S (4.29 μM), or 4X M2S (17.17 μM) for a period of 24 h. The expression of acetylated histone-H3 was examined 
using Western blotting with β-tubulin used as a loading control. Treatment bars represent the percentage of untreated 
control ± SEM from lysate extracts of 3 independent experiments. Data was analysed using a one-way ANOVA coupled 
with a Bonferroni post-hoc test. * Statistically significant from 0.75% DMSO vehicle control p < 0.05, **** p < 0.0001. 
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(Fig 3.5C). However, in MDA-MB-468 cells 4X of M2S was found to significantly reduce 
cyclin E2 expression by 60% in comparison to DMSO control (Fig 3.5D). Interestingly, 1X 
Figure 3.5 Effect of Jazz-90, vorinostat, M1S, and M2S on cell cycle protein expression in MDA-MB-231 and  
MDA-MB-468 cells 
MDA-MB-231 and MDA-MB-468 cells were seeded at 1.0 × 106 cells/dish in 10 cm cell culture dishes for 24 h at 37°C, 
independently. MDA-MB-231 cells were treated with 0.75% DMSO, 1X Jazz-90 (1.41 μM), 4X Jazz-90 (5.63 μM), 1X 
vorinostat (2.10 μM), 4X vorinostat (8.40 μM), 1X M1S (2.78 μM), 4X M1S (11.14 μM), 1X M2S (2.63 μM), or 4X M2S 
(10.52 μM) for a period of 24 h. Followed by western blotting protein analysis of A) cyclin B1 and C) cyclin.  
B) MDA-MB-468 cells were treated with 0.75% DMSO, 1X Jazz-90 (5.23 μM), 4X Jazz-90 (20.92 μM), 1X vorinostat 
(5.21 μM), 4X vorinostat (20.83 μM), 1X M1S (1.67 μM), 4X M1S (6.66 μM), 1X M2S (4.29 μM), or 4X M2S (17.17 
μM), for a period of 24 h. Followed by Western blotting protein analysis of cyclin B1 and D) cyclin E2. β-actin was used 
a loading control for cyclin B1 and cyclin E2. Treatment bars represent the percentage of untreated control ± SEM from 
lysate extracts of 3 independent experiments. Data was analysed using a one-way ANOVA coupled with a Bonferroni 
post-hoc test. * Statistically significant from 0.75% DMSO vehicle control p < 0.05, **** p < 0.0001. 
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and 4X of M1S and M2S were found to significantly increase the expression of cyclin D1 in  





To then investigate the mechanism by which cyclin B1 and cyclin D1 levels were being 
modulated, Western blotting was used to determine changes in p53 expression. No significant 
change in p53 protein expression was observed after MDA-MB-231 cells were treated with 
either 1X or 4X the EC50 concentration of any of the four compounds for 24 h when compared 
to the vehicle control (Fig 3.7).  
Figure 3.6 Effect of Jazz-90, vorinostat, M1S, and M2S on cyclin D1 protein expression in MDA-MB-231 cells 
MDA-MB-231 and MDA-MB-468 cells were seeded at 1.0 × 106 cells/dish in 10 cm cell culture dishes for 24 h at 37°C, 
independently. MDA-MB-231 cells were treated with 0.75% DMSO, 1X Jazz-90 (1.41 μM), 4X Jazz-90 (5.63 μM), 1X 
vorinostat (2.10 μM), 4X vorinostat (8.40 μM), 1X M1S (2.78 μM), 4X M1S (11.14 μM), 1X M2S (2.63 μM), or 4X M2S 
(10.52 μM) for a period of 24 h. Followed by Western blotting protein analysis cyclin D1 with β-tubulin used a loading 
control. Treatment bars represent the percentage of untreated control ± SEM from lysate extracts of 3 independent 





3.5 Changes in Hsp90 and NF-κB p65 Expression and Nuclear Localisation 
HDACis have been shown to inhibit Hsp90 activity while other studies have shown Hsp90 
inhibition to suppress the activation and nuclear translocation of NF-κB p65 (Fiskus et al., 
2007; Caldas-Lopes et al., 2009). We next sought to determine if the novel HDACis modulated 
the expression or nuclear localisation of Hsp90 and NF-κB p65. To achieve this, Western 
blotting was performed on whole cell lysates looking for changes in total protein expression 
and a nuclear extraction looking for changes in nuclear localisation of Hsp90 and NF-κB p65 
in TNBC cells.1X and 4X the EC50 concentration of Jazz-90, vorinostat, M1S, and M2S did 
Figure 3.7 Effect of Jazz-90, vorinostat, M1S, and M2S on p53 protein expression in MDA-MB-231 cells 
MDA-MB-231 cells were seeded at 1.0 × 106 cells/dish in 10 cm cell culture dishes for 24 h at 37°C. Cells were then 
treated with 0.75% DMSO, 1X Jazz-90 (1.41 μM), 4X Jazz-90 (5.63 μM), 1X vorinostat (2.10 μM), 4X vorinostat  
(8.40 μM), 1X M1S (2.78 μM), 4X M1S (11.14 μM), 1X M2S (2.63 μM), or 4X M2S (10.52 μM) for a period of 24 h. 
The expression of p53 was examined using Western blotting and β-actin used as a loading control. Treatment bars 
represent the percentage of untreated control ± SEM from lysate extracts of 3 independent experiments. Data was analysed 




not have any significant effect on total Hsp90 or total NF-κB p65 expression in MDA-MB-231 
(Fig 3.8A; Fig 3.8B) or MDA-MB-468 (Fig 3.8C; Fig 3.8D) cells 24 h post-treatment 
Figure 3.8 Effect of Jazz-90, vorinostat, M1S, and M2S on Hsp90 and NF-κB p65 protein expression 
MDA-MB-231 and MDA-MB-468 cells were seeded at 1.0 × 106 cells/dish in 10 cm cell culture dishes for 24 h at 37°C, 
independently. MDA-MB-231 cells were then treated with 0.75% DMSO, 1X Jazz-90 (1.41 μM), 4X Jazz-90 (5.63 μM), 
1X vorinostat (2.10 μM), 4X vorinostat (8.40 μM), 1X M1S (2.78 μM), 4X M1S (11.14 μM), 1X M2S (2.63 μM), or 4X 
M2S (10.52 μM) for a period of 24 h, followed Western blotting analysis for A) Hsp90 and B) NF-κB p65.  
MDA-MB-468 cells were treated with 0.75% DMSO, 1X Jazz-90 (5.23 μM), 4X Jazz-90 (20.92 μM), 1X vorinostat (5.21 
μM), 4X vorinostat (20.83 μM), 1X M1S (1.67 μM), 4X M1S (6.66 μM), 1X M2S (4.29 μM), or 4X M2S (17.17 μM) for 
a period of 24 h, followed by Western blotting analysis for total C) Hsp90 and D) NF-κB p65. β-tubulin was used as a 
loading control. Treatment bars represent the percentage of untreated control ± SEM from lysate extracts of 3 independent 
experiments. Data was analysed using a one-way ANOVA coupled with a Bonferroni post-hoc test. No treatment group 
was significantly different from control. 
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compared to the vehicle control. These findings were concordant with the observation that 1X 
and 4X the EC50 of the four compounds had no significant effect on the nuclear expression of 
Hsp90 or NF-κB p65 in MDA-MB-468 cells 24 h post-treatment as compared to control (Fig 










Figure 3.9 Effect of Jazz-90, vorinostat, M1S, and M2S on nuclear Hsp90 and NF-κB p65 protein expression 
MDA-MB-468 cells were seeded at 2.0 × 106 cells/dish in 10 cm cell culture dishes for 24 h at 37°C. cells were treated 
with 0.75% DMSO, 1X Jazz-90 (5.23 μM), 4X Jazz-90 (20.92 μM), 1X vorinostat (5.21 μM), 4X vorinostat (20.83 μM), 
1X M1S (1.67 μM), 4X M1S (6.66 μM), 1X M2S (4.29 μM), or 4X M2S (17.17 μM) for a period of 24 h, followed by 
Western blotting analysis for nuclear A) NF-κB p65 and B) Hsp90. β-actin was used as a loading control. Treatment bars 
represent the percentage of untreated control ± SEM from lysate extracts of 3 independent experiments. Data was analysed 









Table 3.1 Summary of Results 
1X = one-fold, 4X = four-fold, SEM = standard error of the mean. Time course cytotoxicity P-values reflect a two-way 
ANOVA coupled to a Bonferroni post-hoc test (α = 0.05). Densitometry P-values reflect an one-way ANOVA coupled to 
a Bonferroni post-hoc test (α = 0.05). *Statistically significant compared to the vehicle 0.75% DMSO treatment group  




The current project was designed to study the cytotoxic effects and anticancer mechanisms 
of novel HDACis Jazz-90, M1S, and M2S alongside vorinostat against TNBC cells in vitro. 
Previous investigations in colorectal, lung, and cervical cell lines has shown that the novel 
HDACis have potent cytotoxicity in the micromolar to nanomolar range, hence we 
hypothesised potent cytotoxicity would also be seen in TNBC cell lines. To investigate the 
mechanism underlying cytotoxicity, HDACis were examined for their effects on histone-H3 
acetylation, cell cycle protein expression, and modulation of Hsp90- NF-κB p65 signalling, 
determined by Western blotting. In order to ensure the reliability of results produced by the 
current study it is crucial to correctly interpret findings obtained and understand the limitations 
of the assays performed.  
 
4.1 Critique of Methods 
4.1.1 Cell Lines as Experimental Tools 
In cancer therapy development, in vitro models of TNBC are used in early preclinical phases 
of research to determine drug cytotoxicity and mechanism of action. Cancer cells are an easy 
to manipulate and inexpensive platform to investigate these characteristics. In addition, as a 
result of their rapid proliferative properties they provide an almost limitless supply of cells in 
a relatively short time frame, with similar geno- and phenotypes of the patient sample from 
which they were derived. However, in vitro cell culture experiments do have some drawbacks. 
A key drawback is that maintaining a sterile aseptic environment can be difficult as the risk of 
microbial contamination of cell culture medium, washing reagents, and pipetting instruments 
is very high. Moreover, once contamination has occurred it rapidly spreads between researchers 
sharing lab equipment, hindering the progress of other lab members despite proper sterile 
technique. The source of contamination can be difficult to trace and if not successfully 
determined and appropriately decontaminated infections will reoccur once new cells and 
reagents are brought up. In the current study such a case led to a month ceasure of cell culture 
work and invalidation of samples and data generated in the two weeks leading up to this period. 
Despite such drawbacks if aseptic technique and sterile conditions can be maintained, in vitro 
cell culture studies provide an effective platform to investigate the cytotoxicity and mechanism 
of action of pharmacological compounds. For the current study, MDA-MB-231 and  
MDA-MB-468 cells were chosen as models of TNBC as the former cell line expresses 
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significantly higher levels of NF-κB p65 compared to other breast cancer cells lines, and both 
cell lines are known to express mutant forms of TP53 (MDA-MB-231 Arg280 —> Lys, MDA-
MB-468 Arg273 —> His; Wellcome Trust Sanger Institute, 2018). In addition, both MDA-
MB-231 and MDA-MB-468 cells are tumourigenic in mice, allowing comparable in vivo 
studies to be performed.  
 
4.1.2 Cytotoxicity Determination Using the Sulforhodamine B Assay 
Drug cytotoxicity assays against neoplastic cell lines are commonly performed using an SRB 
or MTT assay. The MTT assay is a colourimetric enzyme-based assay which measures the 
reduction of MTT by mitochondrial succinate dehydrogenase in viable cells to insoluble 
formazan followed by spectrometric analysis at 500-600 nm (Denizot et al., 1986). The amount 
of viable cells is then determined via interpolation from a standard curve of known absorbance-
cell number values. In contrast, the SRB assay is based on the principle that the protein dye, 
SRB, stoichiometrically binds to basic proteins within TCA-fixed cells. Hence, the number of 
viable cells is determined based on the amount of dye extracted from stained cells. In 
comparison to the SRB assay, the MTT assay has some limitations relevant to the current study. 
This includes lack of a linear relationship between cell number and absorbance at cell densities 
greater than 5000 cells/well making interpolation to a standard curve beyond this value 
unreliable (Tonder et al., 2015). In contrast, the greater sensitivity offered by the SRB assay 
was ideal given MDA-MB-231 cells were plated at 8000 cells/well and MDA-MB-468  
15,000 cells/well. Also, given the conversion of MTT to formazan depends on the number of 
viable mitochondria and the mitochondrial metabolic rate, which may be unknowingly 
modulated without compromising cell viability, as could occur by novel compounds with 
unmapped cytotoxic pathways such as Jazz-90, M1S, and M2S. Also, it has been shown that 
MTT is inadvertently reduced to formazan by the free cysteine residue of albumin, a common 
component of cell culture growth medium, where an increase in albumin from 2.5% to 5% 
caused a 54% increase in formazan absorbance at 540 nm (Funk et al., 2007). Hence, relatively 
small differences in the albumin percentage of cell culture media can significantly alter 
absorbance and consequently the apparent drug cytotoxicity, further demonstrating the limited 
statistical sensitivity and specificity of the assay. Ultimately these limitations found in the MTT 
assay may confound drug cytotoxicity, lower assay sensitivity, reduce reproducibility, and 
ultimately compromise comparability between HDACis as compared to the SRB assay. 
Furthermore, fewer steps are required to optimise the SRB assay than the MTT assay leading 
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to an overall simpler and faster protocol (Keepers et al., 1991). Given these considerations, the 
SRB assay was determined to be the optimal method to assess drug cytotoxicity in vitro. 
Though it is notable that the multiple washing and aspiration steps involved in the SRB assay 
can potentially dislodge adherent cells, which would result in an overestimation of drug 
cytotoxicity and a lower EC50 concentration.  
 
4.1.3 Protein Analysis Using Western Blotting 
Western blotting is an extremely common technique in cell and molecular biology research 
to analyse changes in protein expression after drug treatment in both in vitro and in vivo 
samples. The current project used a method based on the Bio-Rad PrecisionAb Western 
Blotting protocol, which consists of four key steps: preparation of protein extracts, organisation 
of the protein mixture by molecular weight with gel electrophoresis, transfer of sorted proteins 
to a carrier PVDF membrane, and specific targeted detection of the target protein via 
appropriate blocking and antibody incubation (Schutz-Geschwender et al., 2004). The current 
project utilised indirect protein detection, where the addition of a secondary horseradish-
peroxidase conjugated goat anti-mouse/rabbit antibody was used to increase assay sensitivity 
and amplify the chemiluminescent signal. The target protein is then visualised as a band on X-
ray film, where chemiluminescence is generated only at the protein of interest, thus only one 
clear band should be visible per sample lane. Hence, Western blotting has proven to be a 
powerful technique where simple equipment can be used to detect specific protein expression 
changes. Though, despite the prevalence of the assay the technique does display several 
limitations. Using hand cut blotting paper can lead to the uneven transfer of proteins, where a 
surface area to large or small can alter electrical resistance during the transfer step reducing 
reproducibility between gels. To overcome this, it is recommended that biological triplicates 
be run in parallel on the same gel. Protein can also be lost to the transfer buffer medium if the 
SDS gel is not in physical contact with the PVDF membrane, commonly as the result of an air 
bubble gap, which can only be determined once transfer is complete. To overcome this, the 
smallest gel size should be used to reduce the probability of air bubbles being introduced into 
the transfer sandwich and a gel roller employed to compress the SDS gel against the PVDF 
membrane. Also, it is difficult to determine the reliability of primary antibodies after re-use as 
manufacturers recommend antibodies to be discarded after 10 blots. However, the amount of 
times a primary antibody can be reused is dependent on the protein concentration on PVDF 
membrane, where a high target protein concentration will consume antibody to a greater extent 
 52 
than a low protein concentration, which is difficult to determine. As a result of these 
technicalities bands can appear faded, skewed, or absent as a result of improper blotting 
technique or a systematic error in the equipment used. Moreover, given the cost associated with 
obtaining many different antibodies and duration of the Western blot assay it can be financially 
draining and laborious to optimise the Western blotting technique for each protein, in which 
case a 96-well enzyme-linked immunosorbent assay may be more appropriate. However, given 
the relatively small number of proteins investigated in the current project and availability of 
equipment a Western blot protocol was employed. Lastly, due to the indirect nature of 
quantification through the use of a chemiluminescent signal and differing exposure times, 
results obtained are considered qualitative or semi-quantitative. 
 
4.1.4 Nuclear Protein Extraction 
Cell fractionation allows isolation and purification of proteins within specific organelles to 
determine localised changes in protein expression. The current study utilised a two-phase 
method where a weakly hypotonic solution of KCl and EDTA was used to induce fluidisation 
and destabilisation of the cell membrane, making cells susceptible to mechanical lysis with a 
micro tissue grinder while sparing the relatively smaller and robust nuclear membrane which 
does not undergo mechanical stress due to the spacing between the mortar and pestle. After 
aspiration and storage of the cytosolic components the insoluble nuclear fraction remains. The 
nuclear fraction is then solubilised with the use of a highly hypertonic solution of KCl and 
EDTA followed by mechanical sonication to lyse the nuclear membrane. The advantages of 
cell fractionation as described include protocol simplicity where only three buffer solutions 
and a tissue grinder set are required to separate intracellular proteins, the low cost of buffer 
components, and the ability to inspect samples under a microscope after each step to ensure 
proper fractionation technique. Though the assay is straight forward to perform there exists 
some limitations in the current procedure. Extraction of the cytoplasmic fraction can be 
contaminated with nuclear components as a result of excessive mechanical grinding, and 
similarly the nuclear fraction can be contaminated with cytoplasmic proteins if the cytoplasmic 
supernatant is not completely aspirated off. The level of contamination can be analysed using 
a quality control check of cytoplasmic specific proteins such as endothelial nitric oxide 
synthase and CCAAT-enhancer-binding protein homologous protein in the nuclear fraction, 
and nuclear specific proteins such as Lamin B1 and TATA-binding protein in the cytosolic 
fraction (Johnson, 2012). Another limitation is the low efficiency of protein harvest from the 
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nuclear fraction given the organelle constitutes 30% of cell volume. To overcome this, cell 
seeding density was doubled relative to cells seeded for whole cell lysate extraction and buffer 
incubation times prolonged to ensure sufficient membrane permeabilisation.   
 
4.2 Interpretation of Results 
 
4.2.1 Cytotoxicity Study 
4.2.1.1 Dose Response Cytotoxicity 
In the current study, HDACis were evaluated for their cytotoxicity against TNBC cells in 
vitro as determined by their EC50 concentration, which was also used to determine appropriate 
concentrations to investigate changes in cell signalling contributing to cytotoxicity. In  
MDA-MB-231 cells the hydroxamate derivative Jazz-90 (EC50 1.41 μM) was found to be 
slightly more cytotoxic than its established parent compound vorinostat (EC50 2.10 μM), 
whereas the hydroxythiopyridone derivatives M1S (EC50 2.78 μM) and M2S (EC50 2.63 μM) 
were found to have relatively similar cytotoxicity. In contrast, investigations in MDA-MB-468 
cells showed Jazz-90 (EC50 5.23 μM) and vorinostat (EC50 5.21 μM) to have similar cytotoxic 
potency. M2S (EC50 4.29 μM) displayed lower cytotoxicity in MDA-MB-468 compared to 
MDA-MB-231 cells, while M1S (EC50 1.66 μM) was found to be more cytotoxic. The 
difference in cytotoxicity between the hydroxamate derivatives cannot be fully explained by 
the greater solubility of Jazz-90 (503.2 μM) compared to vorinostat (249.7 μM) in DMSO, 
attributable to the additional hydrogen bonding capacity of the pyridine and carbothioamide 
nitrogens seen in Jazz-90, given similar cytotoxicity was seen in MDA-MB-468 cells 
suggesting similar bioaccessibility among the two compounds (Cell Signalling, 2018). It is thus 
likely that the MDA-MB-231 TNBC subtype has specific sensitivity to the additional pyridine-
2-carbothioamide group seen on Jazz-90 or is generally more sensitive to drug treatment than 
MDA-MB-468 cells. The greater drug sensitivity of MDA-MB-231 cells compared to  
MDA-MB-468 has been reported previously by Gautam (2017). Using the CellTiter-Glo assay 
it was reported that MDA-MB-231 cells are more sensitive to the cytotoxic effects of the 
HDACis belinostat, panobinostat, and as reported in the current study vorinostat. A similar 
effect was reported by Tate et al., (2012) where 100 nM of panobinostat exposure for a period 
of 24 h was found to reduce MDA-MB-231 cell viability 45% compared to control, while only 
reducing MDA-MB-468 viability 25%. Similarly, Joung et al., (2006) reported the cytotoxic 
EC50 of the HDACi trichostatin A to be 12.5-fold higher in MDA-MB-468 cells compared to 
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MDA-MB-231 cells, 946 nM vs 77 nM. A possible explanation for the drug resistant property 
of MDA-MB-468 cells is the presence of a PTEN mutation (A72fsX5, interpreted as the 
insertion of 5 adenine bases at nucleotide A72 of the PTEN gene resulting in a frameshift; Saal 
et al., 2008). Lu et al., (1999) reported mutation of PTEN promotes TNBC cell proliferation 
and inhibit anoikis, a form of apoptosis initiated by disruption of transmembrane integrins and 
the extracellular matrix, as a result of constitutive PI3K signalling. The research group reported 
that re-expression of wild type PTEN using adenovirus transfection decreased the number of 
viable MDA-MB-468 cells 57% below vehicle control 72 h post-transfection. In addition,  
Lewis et al., (2018) reported treatment of MDA-MB-157 cells, which also have a PTEN 
mutation, with 3 μM of vorinostat increased PTEN mRNA expression 2.2-fold and protein 
expression 1.5-fold compared to the vehicle treatment, which occurred as a result of acetylated 
histone-H3 enrichment at the PTEN promoter. Based on these findings it is possible that 
HDACi treatment may enhance PTEN activity in MDA-MB-468 cells inhibiting apoptosis, 
which manifests as HDACi cytotoxicity resistance compared to MDA-MB-231 cells which 
express wild type PTEN. Another possible explanation for the generally lower cytotoxicity in 
MDA-MB-468 cells compared to MDA-MB-231 may be a result of differences in cell 
morphology. MDA-MB-231 cells tend to grow individually and form a monolayer, while 
MDA-MB-468 cells have a tendency to grow in clusters and adhere together (Kenny et al., 
2007). A clustered morphology may inhibit drug accessibility and penetration into interior 
MDA-MB-468 cells, which may continue to proliferate unaffected by drug exposure.  
Looking at M1S and M2S, the presence of either a methyl (M1S) or ethyl (M2S) linker between 
the Zn2+ binding group and capping group had little effect cytotoxic potency in MDA-MB-231 
cells, whereas in MDA-MB-468 cells a shorter methyl linker appeared to promote cytotoxicity. 
Cytotoxicity studies in MDA-MB-468 cells contrast with reports in HCT116, H460, SW480, 
and SiHA cells where the EC50 of M2S was generally 50% that of M1S, whereas the current 
study found the EC50 of M2S to by 258% greater than M1S (Table 1.3). However, this 
interpretation does not account for the fact that the cytotoxic effect of 5-20 μM of M2S in 
MDA-MB-231 and 5-20 μM of M1S in MDA-MB-468 cells appeared to plateau at 30% cell 
viability, indicating that above 5 μM both analogues have similar cytotoxicity. A possible 
explanation for this is that HDACis induce the expression of a cytoprotective chaperone named 
clusterin. Glaser et al., (2003) reported 5 μM of vorinostat caused a 12.1-fold increase in 
clusterin mRNA expression in MDA-MB-468 cells 24 h post-treatment in comparison to 
control. Liu et al., (2009) showed a similar effect produced by 0.1 μM of trichostatin A and  
3 mM of valproic acid in MDA-MB-231 and MDA-MB-468 cells. To then demonstrate the 
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cytoprotective effects of clusterin on HDACi-mediated cytotoxicity the authors used a terminal 
deoxynucleotidyltransferase dUTP nick end labelling assay to look for changes in TNBC cell 
death with and without siRNA knockdown of clusterin. Clusterin siRNA treatment caused a 
significant 15% increase in apoptotic MDA-MB-468 and MDA-MB-231 cells co-treated with 
0.1 μM of trichostatin A after a treatment period of 48 h, compared to 0.1 μM trichostatin A 
treatment alone, demonstrating clusterin to promote HDACi mediated cytotoxicity resistance 
in TNBC cells in vitro. The authors then showed clusterin to inhibit cytochrome C release and 
activation of the intrinsic apoptotic cascade. 0.3 μM of trichostatin A increased clusterin 
expression within MDA-MB-468 mitochondria with no change in cytochrome C in the 
mitochondrial or cytoplasmic fraction as compared to scrambled siRNA treated  
MDA-MB-468 cells. However, combination treatment of 0.3 μM of trichostatin A and clusterin 
siRNA was found to reduce mitochondrial cytochrome C and increase cytoplasmic  
cytochrome C expression 48 h post-treatment compared to 0.3 μM trichostatin A treatment 
alone. This finding shows HDACi induce clusterin overexpression which then protects  
MDA-MB-468 cells from HDACi mediated cell death through suppression of the intrinsic 
apoptotic cascade. Based on this data, it is possible that M1S and M2S induce clusterin 
expression in MDA-MB-468 and possibly MDA-MB-231 cells, respectively, leading to 
HDACi resistance in a subpopulation of TNBC cells.  
 
Together the data indicates Jazz-90 to compare favourably to vorinostat in the 
 MDA-MB-231 subtype and novel organometallic hydroxamate derivatives such as N1-
(ferrocenyl)-N8-hydroxyoctanediamide (EC50 5.08 μM), but compares unfavourably to second 
generation hydroxamate HDACis such as panobinostat (MDA-MB-231 EC50 100-200 nM,  
MDA-MB-468 EC50 <1 μM; Tate et al., 2012). Also, in comparison to investigations in other 
neoplastic cell lines where the cytotoxicity of the three novel compounds ranged 0.06-1.63 μM 
(Table 1.3), the current study found Jazz-90, M1S, and M2S to be less potent in TNBC in vitro, 
indicating further pharmacophore modifications are required to achieve efficacious 
cytotoxicity in the TNBC subtype.   
 
4.2.1.2 Time-course of Cytotoxicity 
The goal of the current study was to assess the anticancer potential of novel HDACis against 
TNBC cells in vitro. For this reason, a 72 h time-course experiment was performed to 
investigate the cytostatic and cytotoxic effects of Jazz-90, vorinostat, M1S, and M2S at 1X and 
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4X the EC50 concentration at several drug exposure times in MDA-MB-231 and  
MDA-MB-468 cells. It was observed that drug cytotoxicity was time-, dose-, and cell line-
dependent. 
 
In MDA-MB-231 cells, relative to control, 1X the EC50 concentration of vorinostat and M2S 
initiated significant cytotoxicity after 24 h followed by Jazz-90 and M1S after 60 h. This 
finding was also reflected in MDA-MB-468 cells where, relative to control, 1X EC50 of 
vorinostat and M2S initiated significant cytotoxicity after 36 h followed by Jazz-90 and M1S 
after 48 h. These findings suggest vorinostat and M2S more readily enter susceptible TNBC 
cells and induce anti-proliferative effects than Jazz-90 and M1S. However, once susceptible 
MDA-MB-231 cells were killed there was a trend of uninhibited cell proliferation among the 
Jazz-90, M1S, and M2S treatment groups between 24-48 h, indicated by the similarity between 
the treatment and control rate of proliferation (Fig 3.3A gradient of the line). However, once a 
significant period of drug exposure had occurred, at 48-72 h, cytotoxicity is induced in  
MDA-MB-231 cells. The overall cytostatic effect of the four compounds in MDA-MB-231 
cells can be seen from the similarity in cell number at 12 h and 72 h post-treatment. In contrast 
to MDA-MB-231, 1X the EC50 concentration of the four compounds appeared to have a 
cytostatic effect in MDA-MB-468 cells. This can be seen at 48 h post-treatment where the 
significant difference between treatment and control MDA-MB-468 cell number was not due 
to drug induced cell death, but due to a relative increase in cell number in the vehicle control 
group where 1X the EC50 concentration of Jazz-90, vorinostat, and M2S were found to decrease 
cell number by 35.1%, 43.8%, and 36.4%, respectively, compared to cell number at 12 h. 
Furthermore, 1X the EC50 concentration of M2S was found to be the most efficacious cytostatic 
agent in MDA-MB-468 cells, where cell number remained relatively stable at ~6200 cells 
between 24-72 h. Given that MDA-MB-468 cells were plated at a density of 15,000 cells/well, 
it is likely that the cytotoxic effects of M2S occur within the first 24 h of treatment in this 
particular cell line, where the remaining population of MDA-MB-468 cells are not susceptible 
to the anticancer effects of the drug. The cytostatic effect produced by the four compounds at 
1X EC50 could be a result of a reversible static effect on cell signalling, transient metabolic 
shutdown, or a non-reversible or permanent metabolic shutdown such as senescence as was 
reported by Xu et al., (2005). The authors reported that 2.5 μM of vorinostat caused a 15% 
increase in the proportion of polyploidy MDA-MB-231 cells and a 4% increase in the 
proportion of MDA-MB-468 cells 5 days post-treatment. A subsequent study using PKH2 to 
stain HCT116 cells, where the fluorescence intensity of PKH2 is halved every generation as 
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the stain is passed onto progeny showed 0.8 μM of vorinostat inhibited a subpopulation of 
HCT116 cells from undergoing cell division indicated by a lack of change in PKH2 
fluorescence intensity after a period of 72 h compared to control. To then demonstrate that 
vorinostat induced senescence, HCT116 cells were treated with 0.8 μM of vorinostat for a 
period of 5 days followed by staining for SA-β-gal, a marker of senescent cells. After 5 days 
60% of HCT116 cells stained positive for SA-β-gal, demonstrating a low concentration of 
vorinostat was required to induce cell senescence. Based on this data it is possible that 1X the 
EC50 of the HDACis investigate induced polyploidy-dependent senescence inhibiting 
proliferation and ultimately producing the cytostatic effect seen in MDA-MB-231 and  
MDA-MB-468 cells between 24-72 h post-treatment.  
 
It was clear that 4X the EC50 of the four compounds exhibited greater cytotoxic efficacy than 
1X EC50, where significant cell death was initiated after 36 h by all four compounds in both 
TNBC cell lines. Notably, at this higher concentration the hydroxythiopyridone derivatives 
induced greater cytotoxicity than the hydroxamate derivatives at each time point. This is most 
clearly seen in MDA-MB-231 cells at 12 h post-treatment where M1S and M2S significantly 
reduced cell number by 92% and 97% below control, respectively, where it remains until 72 h. 
In contrast, at 12 h post-treatment 4X EC50 of Jazz-90 and vorinostat were found to reduce 
MDA-MB-231 cell number by 7% and 19% below control, respectively. A similar effect was 
seen in MDA-MB-468 cells where 36 h post-treatment 4X EC50 of M1S and M2S were found 
to reduce cell number by 75% and 74% below control, respectively, whereas Jazz-90 and 
vorinostat were only found to reduce cell number by 51% and 49% below control, respectively.  
 
Together this data indicates that in MDA-MB-231 cells 1X the EC50 concentration of  
Jazz-90, vorinostat, M1S, and M2S, and 1X the EC50 concentration of M1S and M2S in  
MDA-MB-468 cells produces a cytostatic effect indicated by the limited change in cell 
viability between 12-72 h post-treatment. In contrast 1X the EC50 of Jazz-90 and vorinostat 
appeared to produce a cytotoxic effect in MDA-MB-468 cells indicated by the downward trend 
in cell number 24-72 h post-treatment. However, at 4X the EC50 concentration all four 
compounds in both MDA-MB-231 and MDA-MB-468 cells appeared to have a cytotoxic effect 
between 12-72 h post-treatment.  
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4.2.2 Protein Expression 
To determine the biological changes occurring prior to cell death while standardising for 
differences in drug cytotoxicity MDA-MB-231 and MDA-MB-468 cells were exposed to 1X 
and 4X the EC50 concentration for a period of 24 h, followed by protein analysis using Western 
blotting. To first determine if the novel compounds were indeed HDAC inhibitors we 
investigated changes in acetylated histone-H3 expression. To then establish if cell cycle 
inhibition may be contributing to cytostasis and cytotoxicity, cyclins associated with the G1, 
G2, and M-phase of the cell cycle were analysed, based on previous studies showing HDAC 
inhibition to induce G1 and G2-phase arrest (Senese et al., 2007; Glaser et al., 2003; Salto-
Tellez and Hooi, 2005; Hui et al., 2006; Zhang et al., 2014; Li et al., 2015). In addition, we 
also sought to determine if HDAC inhibition altered Hsp90 and associated NF-κB p65 
expression.  
 
4.2.2.1 Acetylated Histone-H3 
To determine the efficacy of the novel compounds as HDACis we investigated changes in 
acetylated histone-H3 expression. Compared to control, 1X and 4X EC50 of Jazz-90 and 
vorinostat were found to produce a dose-dependent increase in the expression of acetylated 
histone-H3 in MDA-MB-231 and MDA-MB-468 cells, whereas only 4X EC50 of M1S and 
M2S were able to significantly induce acetylated histone-H3 expression restricted to MDA-
MB-468 cells. This suggests that in relation to its cytotoxicity, Jazz-90 has weaker overall 
HDAC inhibitory efficacy compared to its parent compound vorinostat. The lower efficacy of 
Jazz-90 compared to vorinostat as a HDACi suggests that the additional pyridine-2-
carbothioamide group found on Jazz-90 slightly inhibits association, entry, and binding at the 
HDAC active site compared to the phenyl group seen in vorinostat. This would be similar to 
findings by Sodji et al., (2013) who reported the addition of a bulky 2-
(trifluoromethyl)benzonitrile group to the capping pharmacophore of HDAC inhibitors 
produced a 240-260% increase in the IC50 concentration against HDAC8 compared to a phenyl 
group. A similar finding was reported Muthyala et al., (2015) who reported that the substitution 
of a phenyl side chain for a methyl group at the cap pharmacophore caused a 20% improvement 
in HDACi potency, suggesting improved HDAC binding with a smaller capping moiety. 
Furthermore, Jazz-90 may likely have worse inhibition against HDAC5 as compared to 
vorinostat (IC50 3.6 μM) as a result of the compound’s larger capping group, based on a report 
by Wagner et al., (2013). The authors showed that the substitution of the phenyl capping group 
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on vorinostat with large aromatic substitutions such as a hydroxyoctanediamide or tri-phenyl 
benzamide diminished HDAC5 IC50 potency to >5 μM. However, to confirm the exact changes 
in HDAC subtype inhibition a HDAC inhibitory profile of Jazz-90 will need to be performed, 
though the compound appears to have weaker HDAC inhibitory effects than vorinostat. 
Looking at the hydroxythiopyridone derivatives, only a high concentration of M1S and M2S 
were able to induce significant expression of acetylated histone-H3, indicating present but poor 
HDAC inhibition efficacy. A possible explanation of why this occurred may be attributable to 
the short linker pharmacophore, where M1S contains one –CH2 and M2S two –CH2 methylene 
groups. Investigation in hydroxythiopyridone derivatives by Sodji et al., (2013) showed five  
–CH2 groups between the hydroxythiopyridone Zn2+ chelator and triazole capping group to be 
the optimal length for inhibition of HDAC6 and HDAC8. The presence of two –CH2 linker 
units in 1-phenyltriazolylethyl-3-hydroxypyridin-2-thione was reported to have an IC50 of  
>10 μM against both HDAC6 and HDAC8, which decreased to 911 nM and 917 nM, in 1-
phenyltriazolylpentyl-3-hydroxypyridin-2-thione which has five –CH2 methylene units, 
respectively. Increased potency against HDAC6 inhibition was reported to occur as a result of 
stabilising π stacking between the aromatic capping group and Phel-680 at the entrance to the 
active site tunnel of HDAC6, which consequently improved HDACi binding and occupancy. 
In contrast, increased potency against HDAC8 was reported to occur due to the capping group 
seating in a solvent inaccessible pocket of HDAC8 promoting HDACi stability through 
shielding from random Brownian motion of solvent particles which promote drug 
displacement. Hence, the lack of potency of M1S and M2S may be due poor HDAC selectivity 
and poor stability at the HDAC active site resulting from weak electrostatic attraction to 
proximal side chain residues. The difference in cell lines may be attributable to the fact that  
MDA-MB-468 cells have lower levels of basal HDAC expression compared to MDA-MB-231 
cells, hence inhibition of a relatively smaller population of HDACs leads to a more profound 
increase in acetylated histone-H3 expression (Li et al., 2009; Selga et al., 2009)  
 
4.2.2.2 Cell Cycle Regulators 
It has been demonstrated that compounds with the ability to induce cell cycle arrest have 
strong efficacy as anti-proliferative and cytotoxic agents against TNBC cells (Bosch et al., 
2010). The current study indicated that in comparison to control, 1X and 4X the EC50 of 
vorinostat, M1S, and M2S were able to significantly downregulate the expression of cyclin B1, 
a regulator of G2/M-phase cell cycle progression, in MDA-MB-231 cells only. These results 
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are similar to findings made by Zhang et al., (2014) who reported that 5 μM of their novel 
hydroxamate derivative YF479 and 5 μM of vorinostat downregulated cyclin B1 protein 
expression in MDA-MB-231 cells compared to the vehicle treatment after 24 h. Similar 
findings were reported by Shi et al., (2010) who showed that 8 μM of vorinostat reduced cyclin 
B1 expression while also upregulated p21 protein expression in MDA-MB-231 cells 24 h post-
treatment. Furthermore, Lallemand et al., (1999) reported that 6 mM of the HDACi sodium 
butyrate inhibited cyclin B1 and cyclin A protein expression, induced p21 protein expression, 
and promoted G2-phase cell cycle arrest 16 h post-treatment compared to control treated  
MDA-MB-231 cells. The authors then showed that 6 mM of sodium butyrate caused an 80% 
reduction in histone-H1 kinases CDK1 and CDK2 kinase activity after 16 h compared to 
control treatment, indicating modulation of cyclin B1 and p21 expression occurred through 
reduced kinase activity. Subsequent immunoprecipitation of cyclin A associated proteins 
showed that 6 mM of sodium butyrate decreased CDK2 and increased p21 association with 
cyclin A 16 h post-treatment, while immunoprecipitation of cyclin B associated proteins 
showed only decreased CDK1 association with no change in p21 compared to control treated 
MDA-MB-231 cells. Based on this data it is possible that cyclin A-dependent CDK2 activity 
may be required for the formation of active cyclin B1/CDK1 complexes, hence p21 
upregulation may indirectly inhibit the protein expression of cyclin B1. Given these findings it 
is possible that cyclin B1 inhibition reported in the current study is a result of vorinostat, M1S, 
and M2S-mediated inhibition of CDK1 and CDK2 activity in conjunction with p21 
upregulation, leading to inhibition of cyclin A/CDK2 mediated activation of cyclin B1. Based 
on previous studies of HDACi activity in TNBC cells showing cyclin B1 inhibition to correlate 
with G2/M-phase arrest, it is thus likely that the novel compounds M1S and M2S also induce 
G2/M-phase cell cycle arrest. In contrast, Jazz-90 was found to have no significant effect on 
cyclin B1 expression in MDA-MB-231 cells, suggesting the HDAC inhibitory activity of the 
compound to be unrelated to cyclin B1 regulation. Based on the mechanistic findings of 
Lallemand et al., (1999) the lack of Jazz-90-mediated inhibition of cyclin B1 protein 
expression may be due to lack of specific inhibition against histone-H1 kinases. Findings in 
MDA-MB-231 cells were not reflected in MDA-MB-468 cells, where vorinostat, M1S, and 
M2S did not cause a significant change in the expression of cyclin B1. Our findings do not 
appear to align with previous studies which show 5 μM of vorinostat to induce G2/M-phase 
arrest in MDA-MB-468 cells 48 h post-treatment as compared to vehicle control (Munster et 
al., 2001). The difference between reports may be due to vorinostat producing a time-
dependent decrease in cyclin B1 expression after a period of 48 h, as opposed to 24 h, as 
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investigated in the current study. However, given that MDA-MB-468 cells were treated with 
20.83 μM of vorinostat with no significant change in cyclin B1 expression relative to control, 
it is also possible that such a high concentration of drug leads to cell cycle arrest by an alterative 
pathway such as cyclin A or cyclin D1 inhibition. Shankar et al., (2009) investigated the 
efficacy of vorinostat in BALB/c nude mice orthotopically implanted with 2 × 106  
MDA-MB-468 cells followed by 35 mg/kg of vorinostat administered intravenously 4 times 
per week for 3 weeks once tumour volumes were 100 mm3 in size. The authors reported that 
vorinostat treatment caused a 90% reduction in the number of cyclin D1 positive  
MDA-MB-468 cells compared to control treated mice after the treatment period of 3 weeks. 
Based on this data, it is possible that our novel compounds modulate cyclin D1 protein 
expression while having no significant effect on cyclin B1 or cyclin E2 expression in  
MDA-MB-468 cells. 
Further analysis of other cell cycle proteins showed the HDACis to have no significant effect 
on cyclin E2 expression in either cell line compared to control. Interestingly, both 1X and 4X 
of M1S and M2S were found to significantly increase the expression of cyclin D1 in  
MDA-MB-231 cells compared to control. This suggests that the hydroxythiopyridone 
derivatives act to induce cyclin D1, likely via a non-acetylation related mechanism, and as a 
result may promote progression through G1 into S-phase. This finding taken in accordance with 
a study by Kucukzeybek et al., (2017), who reported patients with TNBC tumours with high 
levels of cyclin D1 expression, classified as a receiver operating characteristic analysis value 
of >11.5, to have significantly lower overall 5-year survival compared to patients with low 
levels of cyclin D1 expression, 55% vs 79% (P = 0.044), respectively. Given a sub-population 
of MDA-MB-231 and MDA-MB-468 TNBC cells appeared to be resistant to M2S and M1S, 
respectively, it is possible that surviving TNBC cells may develop a high CCND1 geno- and 
phenotype which may promote malignant TNBC activity. 
 
It has been reported that p53 inhibits transcription of cyclin B1, inhibiting cell viability, and 
that p53 itself is inhibited by HDAC2 activity (Innocente et al., 1999). However, mutant p53 
as found in MDA-MB-231 cells has shown to promote cell survival, hence we sought to 
determine whether a decrease in cyclin B1 protein expression was related to changes in p53 
protein expression in MDA-MB-231 cells (Hui et al., 2006). No significant difference in p53 
protein expression was found between any of the treatment groups and vehicle control in  
MDA-MB-231 cells 24 h post-treatment. This is in contrast to a report by Wang et al., (2016) 
who showed that 2 μM of vorinostat decreased the expression of p53 in MDA-MB-231 cells 
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12 h post-treatment as compared to the vehicle control. However, the authors also reported that 
2 μM of vorinostat caused no difference in p53 protein expression 24-72 h post-treatment in 
comparison to control. It is thus possible that vorinostat and the novel HDACis may produce a 
time-dependent decrease in p53 protein expression before the 24 h time point investigated. 
Furthermore, the study reported that 2 μM of vorinostat decreased p53 phosphorylation with 
no change in total p53 protein levels 24 h post-treatment compared to control, which was linked 
to a decrease in MDA-MB-231 cell viability through suppression of malignant p53 mediated 
transcription of survival proteins such as BCL2L2, FASLG, and CARD8 (Braicu et al., 2015). 
Therefore, it is possible that the novel compounds do indeed alter p53 activity in TNBC cells 
in vitro, which may be at a time point earlier than 24 h. However, the current study found no 
modulation of p53 activity at 24 h post-treatment in MDA-MB-231 cells.   
 
4.2.2.3 Hsp90 and NF-κB p65 
Hsp90 is a chaperone protein which can be inhibited by hyperacetylation as a result of 
HDAC6 inhibition in MCF-7 breast cancer cells (Fiskus et al., 2007). Caldas-Lopes et al., 
(2009) reported that potent inhibition of Hsp90 suppressed the activity of upstream NF-κB p65 
activators IRAK-1 and NAK, which was associated with an 80% decrease in nuclear  
NF-κB p65 activity. Given that NF-κB p65 has been implicated as a significant driver of TNBC 
malignant growth and invasion, we sought to determine if the novel compounds would alter 
Hsp90 protein expression and if this would have a significant effect on NF-κB p65 signalling. 
 
No significant difference in the expression of Hsp90 or NF-κB p65 between any of the 
treatment groups and control, in both MDA-MB-231 and MDA-MB-468 cells 24 h  
post-treatment was found. To then determine if there was any change in nuclear translocation 
of Hsp90 or NF-κB p65, a nuclear extraction assay was performed in MDA-MB-468 cells. 
There was no significant difference in either Hsp90 or NF-κB p65 nuclear protein expression 
between the any of the treatment groups and control in MDA-MB-468 cells 24 h  
post-treatment. This data suggests that in MDA-MB-231 and MDA-MB-468 the compounds 
do not alter Hsp90 or NF-κB p65 activity. The lack of HDACi-mediated changes in Hsp90 
protein expression or nuclear translocation may be due to a lack of significant Hsp90 
acetylation potentially as a result of ineffective inhibition of HDAC6 specifically, a key 
mediator of Hsp90 acetylation. To determine if this is the case specific inhibition of HDAC6 
should be investigated such as through the use of a fluorometric HDAC activity kit. However, 
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given vorinostat is a known potent inhibitor HDAC6 (IC50 144 nM; Sodji et al., 2013) an 
alternative explanation is that the novel compounds do indeed induce Hsp90 acetylation, 
however the level of acetylation may not be significant to modulate chaperoning of upstream 
NF-κB p65 activators IRAK-1 and NAK in MDA-MB-231 or MDA-MB-468 cells (Caldes-
Lopes et al., 2009; Fiskus et al., 2007). To determine if this is indeed the case an 
immunoprecipitation assay for Hsp90 followed by an immunoblot for acetyl lysine should be 
performed in TNBC cell lines following Jazz-90, M1S, and M2S drug treatment. 
 
4.3 Conclusions and Future Directions 
Jazz-90 exhibited the most potent anticancer activity in MDA-MB-231 cells and M1S in  
MDA-MB-468 cells, with vorinostat showing the most efficacious HDAC inhibition. In  
time-course cytotoxicity studies the four compounds displayed a cytostatic effect at 1X EC50 
concentration and a cytotoxic effect at 4X the EC50 concentration. The 1X and 4X the EC50 of 
vorinostat, M1S, and M2S were found to significantly downregulate the expression of cyclin 
B1 in MDA-MB-231 cells only, suggesting that the compounds induce G2/M-phase arrest. 
Based on these findings future studies should investigate if TNBC cell’s resistance to M1S and 
M2S relates to the upregulation of clusterin mRNA transcripts and protein expression. To better 
understand the structure activity relationships between HDACis and HDACs future studies 
should aim to determine the specific HDAC inhibitory profile of Jazz-90, M1S, and M2S, to 
enable comparisons to other hydroxamate and hydroxythiopyridone compounds and associate 
changes in drug structure to specific HDAC inhibition. To build upon this, the cytotoxic 
efficacy and HDAC inhibitory potency of M1S and M2S hydroxythiopyridone derivatives 
containing three to six –CH2 methylene linker groups should be investigated, based on previous 
reports showing that five methylene groups between the Zn2+ chelator and capping group to 
produce optimal HDAC inhibition. Given that the compounds showed significant cytotoxicity 
60 h post-treatment, Western blotting for cleaved caspase-3, cleaved caspase-8, and cyclophilin 
A should be performed at this time point to determine if cell death is mediated through the 
intrinsic apoptotic cascade, extrinsic cascade, or necrosis, respectively. Furthermore, flow 
cytometric analysis of MDA-MB-231 cells treated with M1S and M2S should be performed to 
determine if the significant decrease in cyclin B1 expression reported in the current study does 
indeed associate with G2/M-phase arrest. Also, given that the novel HDACis caused no change 
in Hsp90 expression, changes in chaperone acetylation and association with IRAK-1 and NAK 
should be investigated to determine if changes in Hsp90 acetylation indeed correlates with 
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modulation of upstream NF-κB p65 activators, which would elucidate whether Hsp90 
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